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In this  thesis the relation between thyroid hormones and the coagulation system will 
be examined. As an introduction, the hypothalamic-pituitary-thyroid axis, the 
coagulation system and their interactions will be discussed. A short overview of the 
literature preceding the research reported in this  thesis  is about the relation between 
thyroid hormones, the coagulation system, and risk of bleeding and venous 
thrombosis.
Thyroid hormones
The hypothalamic-pituitary-thyroid axis is the regulatory system of thyroid hormone 
action. In the hypothalamus, thyroid releasing hormone (TRH) is  secreted and 
transported to the pituitary gland. Here, TRH stimulates  the production of thyroid 
stimulating hormone (TSH), which in its  turn is released in the circulation and affects 
the functioning of the thyroid gland. The thyroid gland is  located in het ventral part of 
the neck and consists of 2 lobes, connected by the isthmus. The thyroid consists of 
follicles lined by cuboidal epithelioid cells. The thyroid hormones tri-iodothyronine 
(T3) and tetra-iodothyronine (T4) are synthesized in the gland under influence of 
TSH and regulated by negative feedback mechanisms. More T4 than T3 is produced 
and stored, while T3 is  the most active form of the hormone. In several peripheral 
tissues like the liver, muscles  and kidney, T4 is converted into the more active T3 
(this  is done by 5’-monodeiodination). Thyroid hormones bind to nuclear receptors, 
the thyroid hormone receptors (THR). When T3 or T4 binds to the THR (T3 has a 10-
fold greater affinity for the THR), they either activate or repress gene transcription. 
Thyroid hormone influences the basal metabolic rate, resulting from influence on the 
carbohydrate, protein and lipid metabolism, the Na-K pump activity and 
thermogenesis.
Hyperthyroidism is a condition in which the thyroid gland produces and secretes 
excessive amounts  of the free thyroid hormones T3 or T4. Hyperthyroidism is one 
cause of thyrotoxicosis—the hypermetabolic clinical syndrome which occurs when 
there are elevated serum levels of T3 or T4. There are several causes  of 
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hyperthyroidism such as Graves’ disease, toxic adenoma, and toxic multinodular 
goitre. Thyroiditis (inflammation of the thyroid gland) may also cause 
hyperthyroidism, but often progresses to gland dysfunction and, thereby to hormone 
deficiency and hypothyroidism.
Another cause is  oral consumption of excess thyroid hormone tablets (surreptitious 
use of thyroid hormone), as is the rare event of consumption of ground beef 
contaminated with thyroid tissue, and consequently thyroid hormone (termed 
"hamburger hyperthyroidism”). Amiodarone, an anti-arrhythmic drug which is 
structurally similar to thyroxine, may cause either under- or overactivity of the thyroid. 
Finally, hypersecretion of thyroid stimulating hormone (TSH), which is almost always 
caused by a pituitary adenoma, is  also a (very rare) cause of hyperthyroidism. Major 
clinical signs of hyperthyroidism include weight loss (often accompanied by an 
increased appetite), anxiety, intolerance to heat, hair loss, muscle aches, weakness, 
fatigue, hyperactivity, irritability, polyuria, polydipsia, delirium, tremor, pretibial 
myxedema and sweating. 
Hypothyroidism is a pathologic condition in which the thyroid gland produces 
inadequate amounts of the thyroid hormones thyroxine (T4) and triiodothyronine 
(T3). Since iodine is an essential building block to produce T3 and T4, iodine 
deficiency is the most common cause of hypothyroidism worldwide. In parts  of the 
world where iodine is widely available in food, hypothyroidism is most commonly 
caused by Hashimoto's thyroiditis; other causes may include an absent thyroid gland 
or central hypothyroidism due to impaired production of the hypothalamic hormone 
TRH or the anterior pituitary hormone TSH. Central hypothyroidism may occur 
following for example injury to these glands  from physical trauma, compression by a 
tumor or vascular insufficiency. Certain medications may cause hypothyroidism, such 
as lithium-based mood stabilizers, amiodarone and thalidomide. Partial or total 
removal of the thyroid gland also causes hypothyroidism. Clinical symptoms can be 
divided in early and late symptoms. Early symptoms are thin, brittle fingernails; dry, 
itchy skin; weight gain, water retention, myxedema, hair loss, depression, depressed 
reflexes, hypotonia, muscle cramps, muscle weakness, fatigue, cold intolerance, 
bradycardia, elevated serum cholesterol. Late symptoms are thinning of the outer 
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third of the eyebrow, slow speech and hoarse voice, carpal tunnel syndrome and 
hypotension.
The coagulation system
Haemostasis is  the process by which blood loss is prevented. It leads to cessation of 
blood loss to the extravascular space from a damaged vessel. The endpoint of 
haemostasis is reached when the damage to a blood vessel wall is  covered by a 
platelets  and fibrin-containing plug, thereby stopping bleeding. Thereafter repair of 
the damaged vessel can start. 
Under physiological conditions, the vessel wall prevents platelet adhesion and clot 
formation. Haemostasis begins almost instantly after an injury has damaged the 
endothelial lining of the vessel. This damage exposes subendothelium, which 
contains collagen and von Willebrand factor, to the blood components. This initiates 
platelets  adhesion and aggregation at the site of injury; primary haemostasis. Almost 
simultaneously with the initiation of primary haemostasis, secondary haemostasis is 
activated by tissue factor, also released from the vessel wall. Secondary 
haemostasis is a complex system of coagulation proteins in the blood plasma. Its 
goal is to generate large amounts of thrombin when needed, ultimately resulting is 
the generation of insoluble fibrin from soluble fibrinogen to strengthen the platelet 
plug  and allowing adherence and activation of cells involved in vascular repair.
The process of coagulation was originally regarded as a cascade of one factor 
activating the next. The coagulation system is classically divided in two pathways, 
extrinsic and the intrinsic pathway, finally leading to fibrin formation through a 
common pathway (figure 1). The pathways are a series of reactions, in which a 
zymogen (inactive enzyme precursor) of a serine protease and its glycoprotein co-
factor are activated which subsequently catalyze the activation of a next zymogen. 
Rather than a cascade, it is a system in which there are multiple positive and 
negative feedback loops as well as cross-connections between the pathways. 
To achieve fast thrombin generation three phases can be identified: 
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1. Initiation: Following damage to the blood vessel the extrinsic pathway becomes 
activated. Tissue factor (TF), which is expressed by endothelial cells, 
subendothelial tissue and monocytes, is exposed to  factor VII (FVII) and forms an 
activated TF-FVIIa complex. TF-FVIIa in its turn activates Factor X. Together with 
factor V, calcium and phospholipids,  factor X forms the prothrombinase complex. 
This prothrombinase complex activates prothrombin to thrombin. 
2. Amplification: Thrombin formation is amplified by the small amount of thrombin 
generated by the extrinsic pathway in the initiation phase. Thrombin activates the 
intrinsic pathway by activation of factor XI, factor VIII and factor V. This leads to 
the production of activated factor IX and activated factor VIII which together with a 
phospholipid membrane and calcium form a tenase complex, activating factor X to 
activated factor X, again leading to formation of the prothrombinase complex 
which produces large amounts  of thrombin from prothrombin. Thrombin converts 
fibrinogen to fibrin, one of the building block of a haemostatic plug. It also 
activates factor XIII, which crosslinks  the fibrin strands to stabilize the clot. The 
coagulation system remains in a prothrombotic state by the continued activation of 
FVIII and FIX to form the tenase complex, until it is inhibited by anticoagulant 
pathways.
3. Inhibition: Following the amplification phase, several inhibiting mechanisms are 
activated. The activation of factor X (FX) to form FXa by TF-FVIIa is almost 
immediately inhibited by tissue factor pathway inhibitor (TFPI), stopping the 
initiation phase. Protein C is activated by thrombin. Together with protein S and 
phospholipids it degrades activated factor V and activated factor VIII, thereby 
inhibiting coagulation. Antithrombin is also produced, degrading thrombin, 
activated factor IX, activated factor X, activated factor XI and activated factor XII, 
this  way also inhibiting the propagation of coagulation. Furthermore, plasmin is 
generated out of plasminogen to cleave fibrin, inhibiting excessive fibrin formation. 
The complete coagulation system maintains  a balance allowing rapid formation of a 
clot upon injury that is limited to the site of injury. Any imbalance can induce a 
bleeding tendency and a protective effect against venous thrombosis or can lead to a 




Figure 1: the coagulation system (http://en.wikipedia.org/wiki/
File:Coagulation_full.svg).
Venous thrombosis
With an incidence of 1-2 per 1000 person-years, venous thrombosis is the third most 
common cardiovascular disease in Western society (after acute coronary syndrome 
and stroke). Clinical manifestations of venous thrombosis are deep venous 
thrombosis  and pulmonary embolism. Deep venous  thrombosis is  a condition where 
a thrombus develops in the deep veins of the calf or in more proximal veins, such as 
the popliteal, femoral or iliac veins. This leads to obstruction of venous drainage of 
blood. Characteristic symptoms of deep venous thrombosis  are a red, swollen, 
painful leg. Pulmonary emboli develop from deep venous thrombi. A venous 
thrombus formed anywhere in the body can dislodge from its location and move 
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more proximally. The emboli are caught in the first web of smaller vessels they 
encounter: the lungs. This leads  to various symptoms: dyspnea, tachypnea, pleuric 
pain, cough and wheezing, although the clinical presentation is  highly variable.  The 
30 days case fatality rate for deep venous thrombosis  and pulmonary embolism 
combined is 11% and the 1-year case-fatality rate is 23% [1,2]. In more than 6 
percent of all deaths massive pulmonary emboli are found by autopsy. Much 
research has been done on risk factors for venous thrombosis. These risk factors 
can be divided in genetic and acquired risk factors. Genetic risk factors include 
antithrombin deficiency, factor V Leiden mutation, prothrombin 20120A mutation, 
ABO blood group, protein C deficiency and protein S deficiency. Acquired risk factors 
include surgery, plaster cast, cancer, long haul travel, pregnancy, and oral 
contraceptive use [3-6]. 
The recurrence risk of a venous thrombotic event is  much higher than the risk of a 
primary event. The cumulative incidence of recurrent venous thrombosis has been 
described to be 4-11% within the first year and 12-30% in the five years after the first 
event. Incidence rates of recurrence vary between 25 and 46 per 1000 person-years 
[7-10]. While many risk factors for first venous thrombosis are known, this is  not the 
case for recurrent events. Furthermore, the risk profile for recurrent venous 
thrombosis  is different from that of first venous thrombosis. This is the case for for 
example thrombophilia, an increased tendency of the blood to clot. Thrombophilia 
includes deficiencies of the natural anticoagulants antithrombin, protein C, and 
protein S, as well as carriership of factor V Leiden, prothrombin G20210A, and high 
levels  of factors VIII, IX, or XI, homocysteine, and fibrinogen. While thrombophila is 
associated with a 2-10 fold increased risk of a first event, it does not predict risk of 
recurrence [7,9]. Age, also an important risk factor for a first venous thrombosis, 
does not influence risk of recurrence [11,12]. 
Thyroid hormones and the coagulation system
The first time a relation between thyroid disease and venous thrombosis was 
described was  in 1913 by Kaliebe [13]. He described a patient with Graves disease 
and cerebral venous thrombosis and proposed a relation between thyroid hormone 
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and venous thrombosis. Other case reports followed, again describing subjects  with 
hyperthyroidism and cerebral venous thrombosis, suggesting an effect of thyroid 
hormone excess  on the coagulation system [14-18]. Subsequent studies focused on 
alterations in levels  of coagulation factors in patients with thyroid disease and mostly 
confirmed that hyperthyroidism was associated with prothrombotic changes. 
Squizzato et al. reviewed the available literature [19] until 2007 on thyroid hormones 
and their effect on the coagulation system. An important conclusion of their study 
was that there were no high quality papers on this subject. After pooling the available 
studies of low and medium quality they arrived at the following conclusions: In 
subjects with elevated levels of thyroxine, high levels  of von Willebrand factor and 
fibrinogen were observed. In subjects with decreased levels of thyroxine, an 
increased bleeding time was seen together with a prolonged activated partial 
thromboplastin time and prothrombin time and decreased levels of factor VIII, von 
Willebrand factor and fibrinogen. Apart from studies into the effect of thyroid 
hormones on the coagulation system, only one small study had been performed on 
the relation between thyroxine and the risk of venous thrombosis before the start of 
this  thesis in 2007. This  study concerned 50 patients  with provoked, 50 patients with 
unprovoked and 50 controls with no venous  thrombosis [20]. No increased 
prevalence of hyperthyroidism was found in patients with venous thrombosis 
compared with controls. 
The objective of this thesis is  to clarify the relation between thyroid hormones, the 
coagulation factors  and their effect on the risk of haemorrhage, first venous 
thrombosis  and recurrent venous thrombosis. The effect of thyroid hormones  and 
thyroid stimulating hormones in the thyroid axis on the coagulation system is not 
clear in all details. Importantly, it is unknown which coagulation factors are influenced 
by either TSH of FT4 and which are not. Also, claims have been made on a possible 
auto-immune effect of anti-thyroid peroxidase antibodies on the coagulation system, 
and so there could be an effect on the coagulation system of these antibodies. 
Because large studies concerning the effect of thyroid function on the risk of venous 
thrombosis  and haemorrhage are missing, these risks in patients with aberrant 
thyroid function remain unknown. Since risk factors for a first venous thrombosis 
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differ from those of a recurrent venous event, it is also of interest to assess the effect 
of thyroid function on recurrent venous thrombosis. 
Outline of this thesis
 In chapter 2, the effect of levels of free thyroxine (FT4) and thyroid stimulating 
hormone on individual coagulation factors is evaluated in a group of patients treated 
for thyroid cancer. The effect of levels of free thyroxine on the risk for major bleeding 
in a population using vitamin K antagonists is described in Chapter 3. In the TROL 
study, a large Norwegian prospective cohort study, the relation between levels  of free 
thyroxine and risk of venous thrombosis was studied, which is  described in Chapter 
4. Chapter 5, 6 and 7 describe data from the MEGA study, a population based case-
control study in Leiden on the aetiology of venous thrombosis. In Chapter 5, the 
relation between levels of free thyroxine and risk of thrombosis is  studied in more 
detail and in several subgroups. Furthermore, the relation between free thyroxine 
and coagulation factors  is assessed within controls. Because contradictory findings 
have been reported on the effect of low levels of free thyroxine on the risk of venous 
thrombosis, this was assessed in the MEGA study and discussed in chapter 6. In 
chapter 7 the effect of levels of free thyroxine on the risk of recurrent venous 
thrombosis  is reported, as estimated from the MEGA follow up study. Chapter 8 
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Thyroid dysfunction is known to affect the coagulation system [19,21-23]. In patients 
with overt hypothyroidism decreased levels of factor VIII (FVIII), fibrinogen and von 
Willebrand factor (VWF) have been observed [24,25]. In hyperthyroidism the 
opposite has consistently been described, i.e. elevated levels of VWF and fibrinogen. 
Free thyroxine (FT4) and thyrotropin (TSH) are inversely related: when FT4 rises, 
TSH drops and vice versa. Although it is generally assumed that levels of FT4 are 
related to altered coagulation parameters, it remains unknown whether this effect on 
coagulation is  partially mediated by thyrotropin (TSH). Recently more evidence is 
provided showing that TSH can have a direct effect itself in peripheral tissues such 
as bone, adipose tissue and muscle, mediated via the TSH receptor [26-28]. The 
question whether TSH, independently of FT4, also affects the coagulation system 
remains therefore to be answered. We had the opportunity to study the separate 
effects of these hormones in two series of patients successfully treated for well-
differentiated thyroid carcinoma. We set out to examine and disentangle the effect of 
changes in TSH and serum FT4 levels on FVIII, VWF and fibrinogen. Additionally, we 
explored the influence of FT4 and TSH levels on other coagulation factors.
Methods
The analyses were based on data from patients treated for well-differentiated thyroid 
carcinoma. Patients  were derived from two studies initiated to assess the influence 
of thyroid hormone on: 
1.  Metabolism and gene expression in relation to heart rate and blood pressure 
[29]. 
2.  Bone metabolism [30]. 
Eligibility criteria for these studies  have been described previously [29,30]. In short: 
patients > 18 years and cured from well-differentiated thyroid carcinoma in need for 
diagnostic thyroglobulin (TG) stimulation were eligible. Prior to diagnostic protocol, 
patients from the Department of Endocrinology of the Leiden University Medical 
15
Hypo-TSH
Center (LUMC) were asked to participate in the study. For both studies written 
informed consent was obtained and the Medical Ethics Committee of the LUMC 
approved both protocols.
The rationale behind the design is  that serum TG determined after maximal TSH 
stimulation is used as tumour marker in these patients. Cure is defined as 
undetectable TG levels and negative total-body scintigraphy. To assess maximally 
stimulated TG, high levels of TSH are induced by withdrawal of levothyroxine, or by 
administration of recombinant human TSH (rhTSH) while continuing levothyroxine 
treatment [31]. Characteristics of patients assessed with either thyroxin-withdrawal or 
rhTSH stimulation can assumed to be similar. According to method of TG stimulation 
two groups were studied: 
1. Eleven patients undergoing thyroxine-withdrawal were included. Blood 
was sampled at two points. The first blood sampling was performed after 
participants had stopped their levothyroxine treatment for 4 weeks. 
Participants restarted their levothyroxine treatment and eight weeks 
following the first blood sampling, the second blood sample was drawn. 
2. Seventeen patients received rhTSH (Thyrogen) and blood samples were 
again drawn at two time points. The first sample of blood was drawn when 
participants were at their regular substitution level. During two subsequent 
days 0.9 mg rhTSH was administered intramuscularly, and after 4 days 
the second sample was drawn. 
Biochemical analysis 
Levels  of fT4 and TSH were measured with an ELISA with a Modular Analytics  E-170 
system; intra-assay CV 1.6-2.2% and 1.3-5.0% respectively (Roche Diagnostics, 
Almere, The Netherlands). Coagulation levels  were measured by activity assays for 
factor II, (STA Factor II), factor VII (STA Factor VII), factor VIII (STA deficient VIII), 
factor IX (STA factor IX) antithrombin (STA Antithrombin III) and protein C 
(chromogenic method, STA protein C chromogen) and by antigen assays  for von 
Willebrand Factor (STA Liatest® VWF) and protein S (Liatest® Protein S and 
Liatest® Free Protein S), all produced by Diagnostica Stago, Asnières, France. 
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Furthermore, fibrinogen (method according to Claus, STA Fibrinogen, Diagnostica 
Stago, Asnières, France), thrombin-antithrombin complex antigen (Enzygnost TAT 
micro; Dade Behring, Marburg, Germany) and prothrombin fragment 1+2 antigen 
(Enzygnost F1+2 (monoclonal); Dade Behring, Marburg, Germany) were measured. 
All tests were performed in duplicates. 
Statistical analysis
Median values and their ranges were determined for all measurements. Mean 
differences of the pre- and post-treatment levels for each coagulation factor within 
each patient were calculated with their 95% confidence intervals (CI95). All statistical 
analyses were performed using SPSS 16.0 for OS X (SPSS Inc, Chicago, IL).
Results 
The thyroxine withdrawal group study group consisted of 7 women and 4 men, 
median age 44 years (range: 29-56). Ten participants were treated for papillary 
carcinoma, 1 for a follicular carcinoma. The median time from surgery and 
radioactive iodine ablation therapy was 16 months  (range: 8-64). At measurement 1 
(during levothyroxine withdrawal), levels of TSH were high with a median of 133.4 
mU/l while median levels of fT4 were extremely low: 1.5 pmol/L. At measurement 2 
(upon return of the normal suppleted situation), median TSH levels  had decreased to 
0.7 mU/l with median fT4 levels of 24.2 pmol/l. For FVIII, VWF and fibrinogen a clear 
difference was observed between measurement 1 and measurement 2 (FVIII (+39.1 
U/dl CI95 6.8 to 71.4), FIX (+30.8 U/dl CI95 20.8 to 40.9), VWF (+32.0 U/dl CI95 
13.1 to 50.8) and fibrinogen (+0.6 g/l CI95 0.2 to 1.0)). In addition as shown in Table 
1, factor II (FII), antithrombin (AT), and total protein S increased to a lesser extend at 
measurement 2, while levels of factor VII (FVII) and protein had decreased. No clear 
changes were observed for prothrombin fragment 1+2 (F1+2) and thrombin-
antithrombin complexes (TAT) (Table 1).
The recombinant TSH group consisted of 1 male and 16 female patients. Median 
age of these patients was 49 (range 25-86) years. Fifteen participants  had a papillary 
carcinoma and 2 patients a follicular carcinoma. The median time from surgery and 
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radioactive iodine ablation therapy was 37 months (range 13-303). A strong increase 
in median TSH levels was seen between measurements, i.e. from 0.1 mU/L in the 
normal situation to 23.9 mU/L after rTSH suppletion. Median levels of fT4 did not 
differ materially between the two measurements: 21.3 pmol/L versus 22.1 pmol/L. In 
this  group, no clear differences in levels of FVIII, FIX, VWF, fibrinogen or the other 
coagulation factors were observed between the two measurements (Table 2).
Discussion
In patients in whom stable fT4 levels accompanied increasing levels of TSH, no clear 
effect on coagulation parameters was observed. In patients who changed from a 
state of high TSH and low fT4 to low TSH and slightly elevated fT4 levels, a clear 
rise in FVIII, FIX, VWF and fibrinogen was demonstrated. These results  suggest that 
changes in coagulation factors related to thyroid function are mainly mediated by fT4 
and not by TSH. 
The findings  of an increase of FVIII, fibrinogen, FIX and VWF with rising levels  of fT4 
is  consistent with previous literature [19,32-34]. Furthermore we showed an effect on 
nearly all other measured coagulation factors with changing levels of fT4. There are 
two possible mechanisms for the effect of thyroid dysfunction on coagulation: first 
excess or deficiency of thyroid hormone and secondly, auto immune diseases 
associated with thyroid disease can have an effect on coagulation [35]. In this study 
we focused on the first option. Excess or deficiency of thyroid hormone can lead to 
either a disequilibrium in the production and clearance of coagulation factors or a 
heightened of lowered direct genetic transcription of coagulation factors  [36]. Up to 
this point, no definitive answer is at hand explaining the exact mechanism.
Due to the setting of this study within patient care, there were differences between 
the two groups: Firstly, the mean TSH that we measured was higher in the 
withdrawal (141.7 mU/l) than in the recombinant TSH group (23.2 mU/l). However, it 
is  known that shortly after rhTSH administration levels of TSH rise to values above 
100 mU/L [37] and decrease gradually towards the values like those we measured a 
few days later. This  means that both groups are likely to have been exposed to 
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similar peak levels of TSH. Secondly, there were only 4 days of rhTSH stimulation in 
the recombinant TSH group. It may be argued that this period is too short to 
demonstrate an effect on the coagulation system. However, in several studies using 
a direct trigger for activation of the coagulation system changes in coagulation 
parameters were observed within 5 to 8 hours [38-40]. Also, direct in-vivo stimulation 
of hepatocytes with T3 showed a clear response in fibrinogen and coagulation factor 
II and X within 12 hours. This effect was even more pronounced after 24 hours [36]. 
In studies  on venous thrombosis after orthopaedic surgery, within 4 to 5 days after 
surgery, fatal pulmonary emboli occurred [41], reflecting a clear activation of the 
coagulation system within this time frame. Given these observations, if any effect is 
present, we would expect that 4 days of high TSH exposure would be more than 
sufficient to result in a demonstrable difference between pre- and post-testing. 
Despite these limitations we observed clear changes  in levels  of coagulation 
parameters only with rising levels of FT4, and not with changing TSH levels. 
Recently it was found that higher levels of FT4 resulted in an increased risk of 
venous thrombosis [42]. In our study, the changes in coagulation parameters we 
found did not point unequivocal in a pro- or anticoagulant direction, but the large 
increases in FVIII and FIX accompanying support a prothrombotic effect of 
hyperthyroidism.
In conclusion, the results from our study suggest that a rise in thyroxine level is 
associated with increasing FVIII, FIX, VWF and fibrinogen levels, and that this  shift is 
not primarily a result of high TSH levels. An overall shift in other coagulation factors, 
mostly towards a pro-thrombotic tendency was also observed.
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Table 1: Effect on coa          
levels of TSH (thyroxi   
gulation parameters
ne withdrawal group)










1.5 (0.0-2.4) 24.2 (17.4-31.2) 23.4 20.4 to 26.3
TSH (mU/L)
Ref: 0.3-4.7 mU/L
133.4 (99.1-191.9) 0.7 (0.0-3.0) -141.7 -164.7 to -118.6
F1+2 (pmol/l) 125 (100-284) 158 (91-1888) 7.7 -47.0 to 62.5
TAT (ug/l) 2.3 (1.9-18.2) 2.7 (2.1-72.5) -1.0 -6.5 to 4.6
AT (U/dl) 104 (82-141) 116 (90-152) 13.4 5.0 to 22.0
Protein C (U/dl) 132 (99-200) 113 (91-163) -13.6 -22.8 to -4.3
Total Protein S (U/dl) 107 (88-143) 106 (93-160) 7.0 -0.1 to 14.2
FII (U/dl) 114 (83-137) 122 (92-150) 8.5 2.1 to 14.9
FVII (U/dl) 136 (106-213) 105 (88-157) -29.9 -46.4 to -13.4
FVIII (U/dl) 95 (55-155) 133 (84-219) 39.1 6.8 to 71.4
FIX (U/dl) 96 (70-134) 141 (101-171) 30.8 20.8 to 40.9
Fibrinogen (g/l) 3.1 (2.0-3.9) 3.7 (2.5-4.6) 0.6 0.2 to 1.0
VWF (U/dl) 79 (51-120) 102 (67-186) 32.0 13.1 to 50.8
TSH: Thyroid stimulat            
factor II; FVII: factor VI            
von Willbrand factor; C     
ing hormone; AT: Anti
I; FVIII: factor VIII; FIX
I 95; 95% confidence i
thrombin; F1+2: pr




nt 1 and 2; FII:
n complex; VWF:
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Table 2: effect on coag           
of fT4. (Recombinant h   
ulation parameters
uman TSH group)










21.3 (15.2-27.0) 22.1 (17.8-27.2) 1.0 0.1 to 1.9
TSH (mU/L)
Ref: 0.3-4.7 mU/L
0.1 (0.0-3.0) 23.9 (5.5-46.7) 23.2 17.4 to 29.1
F1+2 (pmol/l) 258 (124-392) 204 (108-343) -30.5 -69.0 to 7.9
TAT (ug/l) 3.9 (2.3-21.9) 3.4 (2.0-23.8) 1.3 -3.2 to 5.8
AT (U/dl) 126 (107-145) 118 (101-140) -1.7 -6.4 to 3.0
Protein C (U/dl) 125 (90-150) 122 (80-140) -3.9 -8.0 to 0.2
Total Protein S (U/dl) 126 (94-159) 124 (88-169) -2.1 -5.6 to 1.4
FII (U/dl) 113 (95-130) 111 (99-126) -3.0 -7.1 to 1.1
FVII (U/dl) 118 (90-172) 112 (95-153) -8.8 -15.3 to -2.3
FVIII (U/dl) 123 (71-324) 138 (59-258) -10.3 -54.1 to 33.4
FIX (U/dl) 160 (114-234) 160 (97-214) -12.7 -25.7 to 0.3
Fibrinogen (g/l) 3.7 (2.4-4.6) 3.8 (2.3-5.6) 0.1 -0.2 to 0.4
VWF (U/dl) 105 (61-316) 150 (44-293) 7.3 -16.8 to 31.4
TSH: Thyroid stimulating           
factor II; FVII: factor VII           
VWF: von Willbrand fact       
hormone; AT: Antith
; FVIII: factor VIII; F
or; CI 95; 95% confid
rombin; F1+2: proth









Major haemorrhage during vitamin K antagonist treatment: 














Annually, approximately 1-3% of patients treated with vitamin K antagonists (VKA) 
suffer from major haemorrhage. Since high levels of free thyroxine (FT4) are 
associated with increased thrombosis risk, the aim was to assess whether low levels 
of FT4 contribute to major haemorrhage in patients under VKA treatment.
Methods
The FACTORS study is a case control study in patients using VKA treatment 
including 110 cases with major haemorrhage. Controls were 220 matched 
participants treated with VKA without major haemorrhage. Odds ratios (OR) and 95% 
confidence intervals (CI95) for the association of FT4 levels and major haemorrhage 
were calculated for different FT4 cutoffs by conditional logistic regression. 
Results
In patients with a FT4 level below 13 pmol/l the risk of major haemorrhage was 5-fold 
increased (OR 5.1, CI95 0.9 to 28.6) compared with patients with a FT4 above 13 
pmol/l. At a cut-off of 14 pmol/l the risk was 3-fold increased (OR 2.9, CI95 1.0 to 
8.5). High levels of FT4 did not affect bleeding risk. No clear effect of TSH and 
thyroid peroxidase antibodies was seen on the risk of major haemorrhage.
Conclusions
These results  indicate that FT4 levels below 14 pmol/l play a role in the aetiology of 





Vitamin K antagonist treatment (VKA) is used for several indications where anti-
coagulation is needed, such as the treatment and prevention of venous thrombosis 
or the prevention of cerebrovascular accidents in patients with atrial fibrillation. 
Haemorrhage is  an important complication of anticoagulant treatment. Annually, 7-10 
% of patients treated with VKA suffer from haemorrhage, and 1-3% from major 
haemorrhage [43,44]. Several risk factors for a bleeding tendency have been 
identified, such as co-morbidities, older age and use of co-medication [43,44]. 
Recently the relation between thyroid hormone and the coagulation system has 
gained interest as a focus of research [19,21,22,35,45]. High levels of free thyroxine 
(FT4) are associated with high levels  of factor VIII (FVIII), von Willebrand factor 
(vWF), fibrinogen and factor IX (FIX) [19,46,47] and are a risk factor for venous 
thrombosis  [42,48,49]. On the other side of the spectrum, low levels of FVIII, vWF 
and fibrinogen have been described in hypothyroidism resulting in a protective effect 
on the risk for venous thrombosis [19]. It has also been reported that low levels of 
FT4 may lead to acquired von Willebrand syndrome [45]. Low levels of FVIII and 
vWF are a risk factor for major haemorrhage [50]. Since FVIII and vWF are 
influenced by FT4, low FT4 levels may also influence bleeding risk in patients under 
VKA treatment. 
FT4 can exert its  effect on the coagulation system also in yet another way. It is 
known that FT4 has an effect on the pharmacodynamics  of VKA, with different levels 
of FT4 resulting in different international normalized ratio (INR) values [51,52]. 
Importantly, VKA dose is continuously adapted by the anticoagulation clinics to 
ensure therapeutic INR range. This prevents a clinical effect of FT4 on INR levels in 
this study. 
The aim of the present study was to assess whether the level of FT4 plays a role in 




Patients and data collection
The study design of the FACTORS (FACTors in ORal anticoagulant Safety) case-
control study has been described in a previous paper [53]. In short, in the registries 
of two Anticoagulation Clinics (Leiden and Amsterdam, The Netherlands) all patients 
with bleeding complications between 1999 and 2001 were identified and these 
complications were classified as minor or major. Patients with major haemorrhage 
under VKA treatment were included as cases. Major haemorrhage was defined as 
haemorrhage leading to death or hospitalization; a haemoglobin decrease >1.25 
mmol/l; intracranial, intramuscular, joint or intraocular haemorrhage. In total, 110 
cases were included in the study. Two control subjects (i.e. patients under VKA 
treatment without haemorrhage) per case were selected from the same registries 
and matched for age (10 year age strata), sex, indication of VKA therapy, 
anticoagulation clinic, type of VKA and whether individuals were still on active 
treatment at time of data collection. If, for example, a case on VKA treatment for 
atrial fibrillation was included, two controls on VKA treatment for atrial fibrillation were 
included. A total of 220 controls was included. The study protocol was approved by 
both the ethics  committees of the Leiden University Medical Center and the 
Amsterdam Medical Center. 
Patients and controls were visited at home by a trained research nurse, with a 
median of 14 months after the bleeding event. Patients  completed a questionnaire 
and citrated blood was drawn from the antecubital veins, kept at 4°C and centrifuged 
for 20 minutes at 2250*g within 2 hours from collection and stored at -80°C. 
Information on medication use was collected. Ten cases and 15 controls were 
treated with amiodarone, 0 cases and 9 controls  received levothyroxine treatment 
and 2 controls were on thyreostatics. Bearing in mind the 1:2 ratio in which the cases 
and controls were recruited, amiodarone use was evenly distributed in cases and 




Levels  of FT4, thyroid stimulating hormone (TSH) and thyroid peroxidise antibodies 
(antiTPO) were measured in the available citrated plasma samples (103 cases and 
213 controls; TSH in 103 cases and 208 controls) using commercially available 
assays (ADVIA Centaur® immunoassay system, Siemens Healthcare Diagnostics, 
Marburg, Germany). As these tests have not been validated by the manufacturer for 
use with citrated plasma, studies comparing TSH and FT4 in plasma and serum 
have been performed [42]. Only small systematic differences were detected and 
linear regression analysis showed a strong association between levels of FT4, TSH 
and AntiTPO measured in serum and plasma (regression coefficients: β≥0.92).  The 
laboratories reference range in plasma was 10 to 24 pmol/l for FT4 and 0.32-4.32 
mU/l for TSH. 
Statistical analysis
FT4 results were returned by the routine laboratory in round numbers. Actual 
reported values of FT4 were used as cut-off points  (FT4 <13, <14, <15, <16, >21, 
>22, >23, >24 pmol/l). Categorizing FT4 based on percentiles  was not possible due 
to the rounded number used to report FT4. TSH and AntiTPO results were returned 
with 2 and 1 decimals respectively, and cut-off values for the 2.5th, 5th, 10th, 20th, 80th, 
90th, 95th and 97.5th percentiles  were calculated in the control population. To study 
the effect on bleeding risk of high levels of FT4, TSH or anti-TPO, we contrasted 
individuals with levels above the cut-off to those with levels  below the cut-off, and 
vice versa for the analysis of the effect of low levels. These analyses were repeated 
for the various cut-off levels. Odds ratios (OR) and 95% confidence intervals (CI95) 
were calculated with conditional logistic regression to take the matched design into 
account.  As density sampling for the controls was  performed, the OR is identical to 
the rate ratio [54]. Analyses were stratified for men and women. In our analysis we 
tried to disentangle pathways through which FT4 might influence bleeding risk. An 
effect of FT4 via VKA metabolism was considered unlikely, as changing INR levels 
are continuously adapted to and kept in tight range. To assess whether FT4 levels 
exert an effect on bleeding risk mediated by VWF and FVIII levels, we ran two 
logistic models: one including VWF and FVIII and a model without these two 
variables. If the effect of FT4 is mediated through VWF and FVIII, the adjusted model 
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is  likely to show an attenuated effect (i.e. an odds ratio towards 1.0), compared to 
the unadjusted model. The INR used was the last known INR before the event for 
cases and the last known INR before blood sampling in the controls. All statistical 
analyses were performed in R version 2.12.1 [55] (packages: foreign_0.8-41 [56] and 
survival_2.36-5 [57]). (R Development Core Team (2005). R: A language and 




The study population consisted of 110 cases and 220 controls (Table 1). Median age 
of the cases was 66.5 years (p2.5 to p97.5: 32.6 to 84.4) and 70.9 years (p2.5 to 
p97.5: 38.3 to 85.1) in the controls. Of both cases and controls 60% were men. Forty 
four percent of the cases and 38% of the controls used phenprocoumon, the others 
used acenocoumarol. 
Effect of FT4 on bleeding risk
Patients with a FT4 level below 13 pmol/l had a 5-fold increased risk (OR 5.1 CI95 
0.9 to 28.6) for major bleeding compared with patients with FT4 levels above or 
equal to 13 pmol/l (Table 2). At a cut-off of 14 pmol/l the risk was 3-fold increased 
(OR 2.9, CI95 1.0 to 8.5). No clear attenuation of the effect was  seen adjusting for 
INR, VWF or FVIII, meaning that it is unlikely that the effect of FT4 on bleeding risk is 
mediated through these factors. No clearly increased or decreased risk could be 
shown for high levels of FT4, i.e., an OR of 0.6 (CI95 0.2 to 2.3) was found for a cut-
off of 23 pmol/l and an OR of 1.2 (CI95 0.3 to 5.0) for a cut-off of 24 pmol/l. Stratified 
analysis by sex revealed odds ratios in women ranging from 5.1 (CI95 0.9 to 28.6) at 
a FT4 level of 13 pmol/l to an OR of 0.8 (CI95 0.2 to 4.4) at 24 pmol/l. In men, the 
odds ratio ranged from 2.9 (CI95 0.5 to 17.6) at 13 pmol/l to 0.3 (CI95 0.0 to 3.5) at 
23 pmol/l (Table 3). 
 At the 97.5th percentile, no association between TSH and bleeding risk was shown 
(OR 1.1, CI95 0.3 to 4.6) (Table 4). At lower levels of TSH, an increased risk for 
major haemorrhage was observed, gradually rising to an OR of 3.6 (CI95 1.0 to 13.3) 
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at the 2.5th percentile. Analysis  of AntiTPO showed no effect of these antibodies on 
the risk for major haemorrhage under VKA treatment (Table 4). 
Discussion
In this case-control study we assessed the association between FT4 and the 
occurrence of major haemorrhage in patients under VKA treatment. We found a 5-
fold increased risk of major haemorrhage in patients with low levels  of FT4 (<13 
pmol/l) relative to patients with higher FT4 levels. Notably, this  effect was found 
within the normal range of FT4 levels. In this  study, pathway via INR, neither a 
pathway via VWF and FVIII could be found as  explanation for the association 
between FT4 levels and bleeding risk.
Unexpectedly, an association with bleeding risk was observed for lower TSH levels. 
This, however, is not in accordance with the increased risk at lower levels  of FT4 
bearing in mind the negative feedback connecting TSH and FT4. An explanation for 
the increased risk with both low TSH and low FT4 levels could be the presence of 
non-thyroidal illness (NTI) (i.e. sick euthyroid syndrome). As  we only found one case 
in our population with both a FT4 and TSH below the 5th percentile, indicating 
possible NTI, NTI as explanation for the found effect is unlikely. FT4 is associated 
with change in coagulation factors whereas TSH is not [46,47]. Therefore a direct 
effect of TSH seems to be biologically less plausible. Alternatively, because levels of 
TSH are related to many cardiovascular parameters and diseases (blood pressure, 
coronary heart disease, glomerular filtration rate and serum lipid concentrations) 
[58-63], it is possible that low TSH is a marker for other factors associated with 
haemorrhage. TSH also tends to increase over time while FT4 levels  remain stable 
[64], potentially making that measured TSH levels do not accurately reflect TSH 
levels at time of the event.  
There are several limitations to this  case-control study. By design, patients were 
included after the occurrence of a major haemorrhage and blood was drawn after the 
event. Therefore measured FT4 levels in our study might not reflect FT4 levels at 
time of the event. It has however been shown that FT4 levels are very stable over 
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time [64,65], making it likely that FT4 levels  after the event are a good reflection of 
FT4 levels at time of the event. Blood was sampled after the acute phase of disease, 
making it more likely for the coagulation parameters to reflect the levels before the 
event. Because of the study size, presented confidence intervals were relatively wide 
and subanalyses were not possible. Lastly, the storage time of the blood samples 
may theoretically have caused changes in the parameters  measurable in the 
samples. If this were the case, these changes would have resulted in random 
misclassification, also resulting in an underestimation of the true effect. Altogether, 
none of the above mentioned limitations  can have explained the increased odds 
ratios found in our study. 
Since this is the first study to show an increased risk for major bleeding with lower 
levels  of FT4, it is too premature to conclude on possible clinical implications. To 
speculate, a more strict regulation of thyroid function in patients on VKAs could be 
indicated, aiming at FT4 levels > 15 pmol/l; also, in patients  with spontaneous 
bleeding on VKA, thyroid status could be checked and, if necessary, corrected to 
prevent more bleeding episodes. At any rate, more research is needed to confirm our 
findings in larger studies and to study clinical implications.
In conclusion, our findings indicate that VKA users with lower levels of FT4 have an 
increased risk for major bleeding.  
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Table 1: Patient characteristics.
 Cases (n=110) Controls (n=220)
Male, n (%) 66 (60%) 131 (60%)
Age at baseline, median (p2.5 to p97.5) 66.5 (32.6 to 84.4) 70.9 (38.3 to 85.1)
Phenprocoumon (%) 48 (44%) 82 (38%)
Indication
Atrial fibrillation 27 62
Cardioversion 1 11
Venous thrombosis 3 6
Mechanical heart valve 18 38
Recurrent venous thrombosis 8 14
Peripheral atherosclerosis 16 29













FT4, pmol/l (p2.5 to 97.5) 17.7 (12.2 to 23.2) 17.7 (13.3 to 24.1)
TSH, mU/l, (p2.5 to p97.5) 1.09 (0.03 to 7.17) 1.17 (0.15 to 6.46)
ATPO, U/dl, (p2.5 to p97.5) 16.6 (16.6 to 1444.4) 16.6 (16.6 to 1444.4)
Subclinical hypothyroidism 6 10
Hypothyroidism 0 0
Subclinical hyperthyroidism 10 8
Hyperthyroidism 1 2
Coagulation
FVIII, IU/dl, (p2.5 to p97.5) 118.5 (75.9 to 190.1) 115.0 (79.4 to 172.3)
vWF ag, IU/dl, (p2.5 to p97.5) 160.0 (66.4 to 323.4) 148.0 (79.0 to 250.7)
N indicates number; p, percentile; FT4, thyroxin       
thyroid peroxidase antibodies; FVIII, factor VIII   






Table 2:            risk for major bleeding in VKA users with different levels of FT4.
FT4 Cases Controls OR1 (CI95) OR2 (CI95) OR3 (CI95) OR4 (CI95)
<13.3 4/99 2/211 5.1 (0.9 to 28.6) 3.5 (0.4 to 31.2) 5.3 (0.9 to 30.8) 3.8 (0.3 to 40.7)
<14.4 9/94 8/205 2.9 (1.0 to 8.5) 5.1 (0.7 to 35.6) 2.5 (0.8 to 7.8) 7.1 (0.9 to 56.1)
<15.6 14/89 29/184 1.0 (0.5 to 2.1) 2.8 (0.9 to 8.8) 1.1 (0.5 to 2.2) 3.6 (1.0 to 12.8)
<16.7 20/83 58/155 0.6 (0.3 to 1.1) 0.9 (0.3 to 2.3) 0.7 (0.4 to 1.3) 1.3 (0.5 to 3.8)
>21.1 14/89 29/184 1.2 (0.5 to 2.4) 0.6 (0.2 to 1.9) 1.0 (0.5 to 2.1) 0.6 (0.2 to 1.7)
>22.2 6/97 20/193 0.6 (0.2 to 1.7) 0.4 (0.1 to 2.0) 0.6 (0.2 to 1.7) 0.4 (0.1 to 2.0)
>23.3 3/100 11/202 0.6 (0.2 to 2.3) 0.3 (0.0 to 2.8) 0.5 (0.1 to 2.1) 0.2 (0.0 to 2.4)
>24.4 3/100 6/207 1.2 (0.3 to 5.0) 0.7 (0.1 to 6.7) 1.1 (0.3 to 4.7) 0.7 (0.1 to 7.5)
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major bleeding in VKA users with different levels of FT4, in men and
FT4 Casesmale Controlsmale ORmale (CI95) Casesfemale Controlsfemale ORfemale (CI95)
<13.3 0/61 0/126 na 4/38 2/85 5.1 (0.9 to 28.6)
<14.4 3/58 2/124 2.9 (0.5 to 17.6) 6/36 6/81 2.9 (0.8 to 11.0)
<15.6 7/54 16/110 0.9 (0.4 to 2.4) 7/35 13/74 1.2 (0.4 to 3.3)
<16.7 10/51 29/97 0.6 (0.3 to 1.5) 10/32 29/58 0.6 (0.3 to 1.5)
>21.1 7/54 20/106 0.7 (0.3 to 1.9) 7/35 9/78 2.6 (0.7 to 9.0)
>22.2 3/58 13/113 0.5 (0.1 to 1.7) 3/39 7/80 1.0 (0.2 to 4.7)
>23.3 1/60 6/120 0.3 (0.0 to 3.5) 2/40 5/82 0.8 (0.2 to 4.4)
>24.4 1/60 1/125 3.5 (0.2 to 55.8) 2/40 5/82 0.8 (0.2 to 4.4)
Referen                 
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Table 4: risk for            
AntiTPO.
major bleeding in VKA users with different levels of TSH and
Percentile TSH (mU/l) Cases Controls OR (CI95)
<2.5 0.12 6/97 5/203 3.6 (1.0 to 13.3)
<5 0.29 10/93 10/198 2.5 (1.0 to 6.3)
<10 0.45 17/86 20/188 2.2 (1.0 to 4.8)
<20 0.72 27/76 41/167 1.8 (1.0 to 3.3)
>80 2.14 21/82 41/167 1.0 (0.6 to 1.9)
>90 2.74 14/89 22/188 1.5 (0.7 to 3.3)
>95 4.47 6/97 10/198 1.2 (0.4 to 3.2)
>97.5 6.60 3/100 5/203 1.1 (0.3 to 4.6)
Percentile AntiTPO (U/dl) Cases Controls OR (CI95)
>80 22.4 19/84 42/171 0.9 (0.5 to 1.6)
>90 155.1 12/91 21/192 1.3 (0.6 to 2.7)
>95 585.2 7/96 10/203 1.5 (0.5 to 4.3)
>97.5 1444.4 5/98 9/204 1.3 (0.4 to 4.1)
Reference group is             
offs) the cutoff va         
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Increased levels of free thyroxine and risk of venous 














Recent studies have shown that high levels  of free thyroxine (FT4), even without 
leading to hyperthyroidism, are associated with a procoagulant state. 
Objectives
The aim of our study was to determine whether high levels of thyroid hormones are 
associated with an increased risk of venous thrombosis.
Patients/Methods
From a prospective nested case-cohort design within the Norwegian HUNT2 cohort 
(1995 – 1997; 66 140 subjects) all patients with venous thrombosis  during follow-up 
(n=515) and 1476 randomly selected age and sex-stratified controls were included. 
Relative and absolute risks for venous thrombosis  were calculated for different cut-
off levels  of thyroid hormones based on percentiles  in the controls. and different 
times between blood sampling and event, 
Results
In subjects with a FT4 level above the 98th percentile (17.3 pmol/l) the odds ratio 
(OR) was 2.5 (CI95 1.3 to 5.0) compared with subjects with levels below this 
percentile. For venous thrombosis within one year from blood sampling, this relative 
risk was more pronounced with an OR of 4.8 (CI95 1.7 to 14.0). Within half a year 
the association was even stronger with an OR of 9.9 (CI95 2.9 to 34.0, adjusted for 
age, sex and BMI). For TSH the relation was inverse and less pronounced. The 
absolute risk within 6 months in the population for FT4 levels above the 98th 
percentile was 6.1 per 1000 person-years (CI95 1.7 to 15.7).
Conclusions
Levels  of free thyroxine at the upper end of the normal range are a strong risk factor 
for venous thrombosis. The risk increased with higher levels of thyroxine and shorter 






Thyroid hormone is  a main regulator of metabolism. Thyroid hormones influence the 
coagulation system, mainly through factor VIII (FVIII) and von Willebrand factor 
(VWF) [19,22,46,47]. These coagulation factor levels rise with increasing levels of 
free thyroxine (FT4) and vice versa. In overt hypothyroidism, this latter effect is 
reversible with hormone substitution [33,34]. Recent findings indicate that the effect 
on the coagulation system is mainly mediated via FT4. Changing thyroid stimulating 
hormone (TSH) levels  with stable free thyroxine (FT4) levels  did not result in 
changes in coagulation factors in two recent studies [46,47,66], while FT4 acts  not 
only on FVIII and VWF but also on factor IX (FIX) and fibrinogen levels [19,46,47,67]. 
Whether or not these alterations in coagulation factors  translate into a higher risk of 
venous thrombosis has not been studied extensively. 
Although there have been several case reports on the relation between (cerebral) 
venous thrombosis and hyperthyroidism, an association between levels of thyroid 
hormone within the normal range and the risk of venous thrombosis  has only 
recently been described in a case control study [42]. In this  study a decreased risk of 
venous thrombosis  was described for low levels of FT4 and an overall 6-fold 
increased risk for FT4 levels above 24 pmol/l compared with levels below this cut-off 
value was found. Due to its design, only relative risks could be calculated in this 
case-control study. Furthermore, blood was drawn at the time of thrombosis, and the 
FT4 levels could potentially have been influenced by the event itself. To avoid these 
problems, we prospectively studied the relationship between levels of FT4, thyroid 
stimulating hormone (thyrotropin, TSH)  and the risk of venous thrombosis in a case-
control study nested within a large population-based cohort (the HUNT2 cohort), 
where blood was drawn at baseline, before the thrombotic event occurred. 
Our aim was to calculate absolute and relative risks for the effect of FT4 and TSH on 
the occurrence of venous thrombosis, with particular attention to the effect of 
different cut-off levels and to time between blood sampling and occurrence of 
41
TROL
thrombosis. To exclude direct immune-mediated effects, we also measured anti-
thyroid peroxidase antibodies (AntiTPO).
Methods
Between August 1995 and June 1997 all inhabitants  of the Nord-Trøndelag county in 
Norway aged 20 years or older (n=94 140) were invited to participate in the second 
Nord-Trøndelag Health Study (HUNT2) [68]. In total, 71% (n=66 140) of all eligible 
individuals participated in the study. All participants  gave their informed consent at 
enrollment in the HUNT2 study. They underwent a physical examination and 
received a questionnaire on several demographic measures, risk factors for 
cardiovascular disease, lifestyle, quality of life, medication use, and co-morbidity 
such as thyroid disease. In addition, serum blood samples were collected (65 291 
samples, 98.7%) at start of follow-up. The inhabitants of the Nord- Trøndelag County 
mainly go to Levanger hospital and Namsos hospital and to the St. Olav university 
hospital in the neighboring county for clinical care, as other hospitals  are far 
removed. In these centers, diagnostic ICD 9 and ICD 10 codes for venous 
thrombosis  were collected up until 1 January 2002 which were subsequently verified 
with hospital records. Events were confirmed when they fulfilled the following criteria: 
DVT was defined by an intraluminal filling defect on ascending contrast venography 
in the leg or arm, a non-compressible venous segment in the popliteal, femoral or 
axillar veins  on duplex ultrasound, or a positive computed tomography (CT) scan. 
Probable DVT was defined as no venous filling on ascending contrast venography 
or no venous flow in femoral, femoral or axillar veins  on duplex ultrasound. PE was 
defined according to the PIOPED criteria[69,70] as a high-probability ventilation/
perfusion (V/Q) scan, i.e. ≥ 2 segmental perfusion defects (V/Q mismatch), a 
perfusion scan with ≥ 2 segmental perfusion defects associated with normal chest X-
ray (X/Q mismatch), or a positive CT scan or by autopsy. Probable PE was defined 
as intermediate probability V/Q scan (1 moderate or large V/Q mismatch). Both 
definite and probable events were included in the analyses. Of all cases, only those 
who participated in the HUNT2 study were included. Patients  with previous 
thrombosis, thrombosis  before enrollment in the HUNT2 cohort or retinal-vein 
thrombosis  were excluded [68]. In total, we identified 515 venous thrombotic events 
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occurring between baseline and 2002. A random sample of 1476 age and sex-
stratified controls was drawn from the original HUNT2 cohort [68]. 
Laboratory measurements
In both the cases and the control subjects  FT4, TSH and AntiTPO were measured in 
the baseline sample. Serum concentrations of FT4, TSH and AntiTPO were analysed 
at Levanger hospital. FT4, TSH and antiTPO were analysed by chemiluminescent 
microparticle immunoassays (CMIA) on an Architect ci8200 (Abbott Laboratories, 
Abbott Park, IL, USA), using reagent kits  from Architect iSystem, USA (free T4 and 
antiTPO) or Ireland (TSH). The laboratory's reference ranges are 9.0 to 19.0 pmol/l 
for FT4, 0.20 to 4.50 mU/l for TSH and <5.61 for AntiTPO. In 446 cases sufficient 
blood was available to measure FT4, TSH and AntiTPO levels. In the controls 1231 
FT4, 1228 TSH and 1230 AntiTPO levels could be measured within the available 
samples. 
Statistical analysis
Descriptives are given as median (2.5th percentile to 97.5th percentile). As cut-off 
points for FT4, TSH and AntiTPO levels we used the 2nd, 5th, 10th, 90th, 95th and 98th 
percentiles in the control group. For the lower percentiles we compared the numbers 
of case and control subjects  below the cut-off percentile with the numbers  above this 
cut-off percentile. For the higher percentiles we did the opposite. We used logistic 
regression to calculate odds ratios (OR) and 95% confidence intervals (95% CI) for 
the association between FT4, TSH and antiTPO and thrombosis risk, adjusting for 
age and sex to take the frequency matching into account. We additionally adjusted 
for body mass index (BMI) as  a continuous variable. Patients with a DVT and PE 
were analyzed separately. We also repeated the analysis  excluding all subjects who 
indicated some form of thyroid disease, i.e., history of hyperthyroidism or 
hypothyroidism, goiter, thyroid disease, use of levothyroxine, use of anti-thyroid 
drugs, thyroid surgery or treatment with radioactive iodine. Since FT4 levels are not 
constant over time, samples that were taken a long time before the event may not 
reflect the actual FT4 level at the time of thrombosis. Therefore we performed 
subanalyses for cases in whom the time between blood sampling and venous 
thrombosis  was less than 1 year or less than 0.5 year. In addition, we stratified the 
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analyses for provoked (immobilisation, travel >8h, paresis, oral contraceptives, 
pregnancy, trauma, surgery and active or non-active cancer) and unprovoked 
thrombosis. 
As our case-control design was nested within a cohort (a case-cohort design), we 
could use numbers of person-years that were available from the original HUNT2 
cohort (data on person-years were available for 65 215 subjects) as a basis for the 
calculation of absolute risks. For each 10 year age-category we calculated the 80th 
and the 90th percentile of FT4 distribution in the controls. For each age-specific 
incidence rate we took the number of cases that occurred for this  age group above 
this  cut-off in the numerator, and 10% or 20% of the person years in the 
denominator. As reference incidence we did the opposite, and took all cases that 
occurred below this cut-off in the numerator and 80 or 90% of the person-years in 
the denominator. We repeated this analysis using only 1 and 0.5 years of follow-up 
by taking the total number of participants times  1 and times 0.5 for the person-years 
calculation. For the calculation of the confidence intervals the Poisson distribution 
was used. Statistical analyses were performed using SPSS 17.0 (SPSS Inc, 
Chicago, IL).
Results
In the HUNT2 cohort a total of 66 140 subjects participated. 515 cases of confirmed 
venous thrombosis  were found in this cohort. In the cases, 44.3% were men and in 
the controls 45.8%. The median age of the cases (70.0 years  (p2.5-p97.5: 29.9 to 
87.0)) at the time of inclusion was similar to the median age at the time of inclusion 
in the controls (70.0 years (p2.5-p97.5: 31.0 to 88.0)). The thrombotic events 
occurred at a median of 33 months (p2.5 to p97.5: 1 to 68 ;range: 2 days to 76 
months) after baseline. The median follow up in the controls was 66 months (p2.5 to 
p97.5: 55 to 77). In the cases 63.3% had a deep venous thrombosis, 30.1% had a 
pulmonary embolism and 6.6% had both a deep venous thrombosis and a 
pulmonary embolism (Table 1). No differences in basic characteristics were observed 
between these 515 cases and the 446 patients in whom blood was available for 
thyroid hormone measurements (Table 1).
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The 446 cases had a median FT4 level of 13.5 pmol/L; (p2.5-p97.5: 10.7 to 17.9), a 
median TSH level of 1.40 mU/L (p2.5-p97.5: 0.37 to 3.53) and a median AntiTPO 
level of 0.8 U/ml (p2.5-p97.5: 0.1 to 433.8). The 1231 controls  had a median FT4 
level of 13.4 pmol/L (p2.5-p97.5: 10.8 to 17.2), a median TSH level of 1.43 mU/L 
(p2.5-p97.5: 0.43 to 3.48) and a median AntiTPO level of 0.8 U/ml (p2.5-p97.5: 0.2 to 
360.7). In total, 28 (6.3%) cases and 66 (5.4%) controls  reported some form of 
thyroid disease (Table 1).  
As shown in Table 2 we found a higher risk for venous thrombosis (OR 2.0, 95%CI 
1.1 to 3.7) for participants with high levels of FT4 (>98th percentile (17.3 pmol/l)) 
compared with subjects with levels of FT4 below this percentile. For participants 
below the 5th percentile the odds ratio was 1.1 (CI95 0.7 to 1.9). When we repeated 
this  analysis  after restricting to cases in whom the thrombotic event happened within 
one year from the blood draw, an odds  ratio of 0.6 (CI95: 0.2 to 2.6) was observed 
for participants with FT4 below the 5th percentile versus participants above the 5th 
percentile. In this group the odds  ratios increased in a dose response relation from 
0.6 towards 3.8 (CI95: 1.4 to 10.3) for participants with FT4 above the 98th percentile 
versus participants below the 98th percentile. When we further restricted the time 
between blood sampling and thrombotic event to half a year, the dose-response 
relation became even more apparent, with ORs rising from 0.8 (CI95: 0.1 to 6.0) for 
the 5th percentile cut-off to 7.7 (CI95: 2.5 to 23.9) for the 98th percentile cut-off. After 
additional adjustment for BMI, we observed an OR of 9.9 (CI95: 2.9 to 34.0) for this 
highest cut-off. Adjustment for TSH had no effect on the risk estimates (Table 2)
We also performed this analysis for levels of TSH (Table 3). No relation with risk of 
thrombosis  was observed when all cases were taken into account. When the time 
period between blood sampling and event was restricted to one year or half a year, 
lower levels of TSH were associated with a somewhat increased risk of venous 
thrombosis. For participants with a TSH below the 2nd percentile an OR of 3.4 (CI95: 
0.7 to 15.4) was found for a time frame of half a year between blood sampling and 
thrombosis. Adjustment for FT4 led to attenuation of all associations (Table 3). 
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Neither for high nor for low levels of AntiTPO did we find an effect on risk of venous 
thrombosis  (Table 4). Also when calculating the OR for cases and controls within and 
out of the reference range, no effect of AntiTPO was seen. 
In a subsequent analysis we looked into the effect of FT4 on the different 
manifestations of venous thrombosis. For patients  with a deep venous thrombosis 
we found an OR of 2.3 (CI95: 1.1 to 5.1), while for patients  with a pulmonary 
embolism (with or without proven DVT) the OR was 2.5 (CI95: 1.0 to 6.5) both at the 
98th percentile. The odds ratios for FT4 on the risk of venous thrombosis after 
exclusion of all patients with a history of thyroid disease did not substantially differ 
from the main findings (data in appendix 1). Also, the odds ratios for patients with 
provoking factors did not differ from patients with unprovoked thrombosis (Table 5).
In all unexposed groups (with FT4 levels  below each cut-off) we found incidence 
rates of approximately 1 per 1000 person years. Incidence rates in the exposed 
group ranged from 1.6 per 1000 person years  (CI95 1.2 to 2.1) when all cases were 
considered using the p90 as cut-off, to an incidence of 6.1 per 1000 person years 
(CI95 1.7 to 15.7) using the p98 as cut-off for subjects  with time between blood 
sampling and event of less than 0.5 year. (Table 6).  
Discussion
In this  prospective population based case-cohort study of 66 140 individuals  we 
examined the relation between levels of FT4, TSH and AntiTPO and the risk of 
venous thrombosis in 446 patients with thrombosis. We found a clearly higher risk for 
increasing levels  of FT4, with an up to a 2.5 fold increased risk for the highest FT4 
levels  (above p98). We also observed higher odds ratios with shorter time from blood 
sampling (up to a 10-fold increased risk for the 98th percentile as cut-off for events 
that occurred within 6 months from blood sampling). The association of TSH with 
thrombosis  risk was much less pronounced. Since we neither observed a dose-
response relation for AntiTPO levels nor an effect of decreasing time between the 
blood draw and the thrombotic event, we suspect that a direct relation between 
AntiTPO and risk of venous thrombosis is unlikely. 
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Other earlier studies have looked into associations between thyroid disease and 
concentrations of coagulation factors, and generally described increased levels  of 
coagulation factors for hyperthyroidism and lower levels for hypothyroidism 
[19,24,32-34,45-47]. A recent study found in 11 patients  treated for thyroid carcinoma 
that a general rise of coagulation factors occurred towards a pro-thrombotic 
tendency when FT4 levels in these patients  went from almost zero to a level slightly 
above the normal range. The rise in FVIII and VWF was most pronounced, but there 
were also obvious effects on FIX and fibrinogen levels [46]. In these patients, a 
similar increase in TSH alone (with stable FT4 levels) had no effect on these 
coagulation factors. This phenomenon, i.e. a direct effect of FT4 on coagulation 
levels  where TSH appears  to have no such action, was recently confirmed in a 
similar study [47]. Also, in our analysis, adjustment for FT4 led to reduction of the 
effect sizes for TSH, which did not occur the other way around. This suggests that 
the association between TSH and thrombosis risk is explained by FT4. It therefore 
appears that, in contrast to FT4, TSH has no direct effect on the coagulation system 
and that the association is  not explained through thyroid disease. It is not known 
what mechanism explains the association between thyroid hormone and the 
coagulation system. A direct effect of FT4 on gene transcription in hepatocytes  and 
endothelial cells leading to a higher production of coagulation factors is likely 
[19,36,69]. Another possible mechanism for the higher risk for thrombosis  are thyroid 
associated auto-immune processes [70], but the lack of association between 
AntiTPO and risk of thrombosis  in the present study does not support this hypothesis 
for this auto-immune antibody. More research needs to be done to establish the 
pathophysiology of this relationship. 
Few clinical, controlled studies have been carried out on this  topic. Recently, a case-
control study was performed on the relation between levels of FT4 and the risk of 
venous thrombosis. In this  study, where an overall 6-fold increased risk for FT4 
levels  above 24 pmol/l compared to levels below this  cut-off was found, blood was 
sampled at the time of thrombosis. This had the advantage that the thyroid hormone 
levels  were measured more or less at the same time that the thrombosis had 
developed, but it could not be excluded that some of the observed effects were due 
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to acute phase effects or non-thyroidal illness [42]. Another study by Danescu et al. 
showed no relation between hyperthyroidism and venous thrombosis. Although this 
is  a study with a large number of subjects, there were several major limitations. No 
data were available on FT4 levels and no information on time between venous 
thrombosis  and diagnosis of hyperthyroidism was given [71]. The design of this study 
combined the strengths of both a case-control and a follow-up design: the former has 
the advantage that an exposure does not need to be measured in the total 
population or cohort, but that a random selection suffices. So, we only needed to 
measure FT4, TSH and Anti-TPO in about 2000 subjects. However, an important 
drawback of a case-control approach is that it is generally not possible to calculate 
absolute risks. Yet, as  our case-control design was nested within a cohort (a case-
cohort design), we could still use data from the original cohort for the calculation of 
absolute risks.  A second disadvantage of a case-control study is that the exposure is 
often measured after the event. This can lead to a dilution of the association, 
especially when, as in the case of thyroid hormone, any abnormalities may have 
been treated by the time the blood is  sampled. It is also impossible to exclude that 
the event is  the cause of the “exposure”. These drawbacks were also prevented in 
our case-cohort design, as the blood was sampled before the event. 
There are potential limitations to the study. Some measurements  were missing, i.e. 
in 69 patients  (13%) and 245 (17%) controls. However, as the only reason why they 
were missing was  a technical one (not sufficient blood available or a test failure), we 
assumed these measurements to be missing completely at random. This was also 
confirmed by the fact that the general characteristics  did not differ between the 
complete group and the included group. Secondly, the time between blood sampling 
and measurement of the thyroid parameters was approximately 12 years, which may 
have made the measurements less  reliable.  However, such misclassification of FT4 
levels  will at most have led to an underestimation of the  effect measures, as such 
misclassification will have been random (i.e. independent of whether or not a subject 
develops venous thrombosis later on). This could therefore not explain our findings 
of a clearly increased risk. Furthermore, blood was sampled at only one moment in 
time and since FT4 levels are not constant over time, they might not reflect the 
actual FT4 level at the time of thrombosis. Such misclassification would again have 
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been random and led to an underestimation of the ORs. We countered this limitation 
by analyses restricted to individuals with blood sampling shortly before the 
thrombosis, and indeed found higher ORs than in the overall analysis. An alternative 
explanation for the higher ORs closer to the event could have been that  non-
thyroidal illness due to co-morbidity was present, which co-morbidity in fact led to the 
thrombosis, rather than the thyroid dysfunction. However, we performed a stratified 
analysis in which we found similar ORs for provoked (i.e. where co-morbidity was 
present) and unprovoked events. We therefore feel that this explanation is unlikely. 
Furthermore, in this  study, no citrated blood was sampled at baseline so we had no 
opportunity to link the clinical data to levels of coagulation factors, to further study 
the underlying mechanism. Lastly, as this study was performed in a general 
population where overt hyperthyroidism is rare (prevalence 0.5% [68]), we found too 
few patients with biochemical hyperthyroidism at the time of blood sampling to 
reliably conclude on the effect of clinical thyroid disease on the risk of thrombosis. 
However, the clear graded association makes it likely that risks  are even higher for 
those with overt hyperthyroidism.  Our study could form the basis of studies in such 
populations.
Our findings may have clinical implications. From an endocrinological point of view, 
one should be alert on signs of venous thrombosis in patients with hyperthyroidism. 
From a haematological point of view, especially patients  with unprovoked thrombosis 
could be screened for hyperthyroidism.
In the previous study on this subject [42,67], the increased risk for venous 
thrombosis  was also found well within reference values for FT4. Interestingly, other 
studies on the association of thyroid function with other clinical states (such as 
glomerular filtration rate, coronary heart disease, serum lipid concentrations and 
blood pressure) have also shown an association of thyroid function within the 
reference range [58-63]. These findings suggest that thyroid function should perhaps 
not be roughly categorised into hypo-, hyper- and euthyroidism, but be used as a 




In conclusion, in this  large, prospective study we showed that high levels of free 
thyroxine are a strong risk factor for venous thrombosis. 
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Table 1: Baseline characteristics.
 Cases (n=446) Controls (n=1228)
male, n (%) 208 (46.6) 575 (46.8)
BMI, median (p2.5 to p97.5) 27.2 (19.7 to 38.6) 26.5 (19.8 to 36.7)
Age at baseline, median (p2.5 to p97.5) 68.5 (29.0 to 87.0) 69.0 (30.0 to 87.3)
DVT, n (%) 282 (63.2)
PE, n (%) 164 (36.8)
History of thyroid disease,n(%) 28 (6.3) 66 (5.4)
Radioactive Iodine treatment, n (%) 7 (1.6) 12 (1.0)
Thyroid surgery, n (%) 9 (2.0) 18 (1.5)
Use anti-thyroid drugs, n (%) 1 (0.2) 1 (0.1)
Use levothyroxine, n (%) 16 (3.6) 44 (3.6)
Thyroid disease reported, n (%) 7 (1.6) 10 (0.8)
Goiter, n (%) 11 (2.5) 20 (1.6)
Hyperthyroidism reported, n (%) 15 (3.4) 17 (1.4)
Hypothyroidism reported, n (%) 18 (4.0) 42 (3.4)
n indicates number of subjects; BMI, body ma        
thrombosis and PE, pulmonary embolism.
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ratios for percentiles of AntiTPO and different time intervals (adjusted for age
Al  l cases TT   E <1 year TTE  <0.5 year
P AntiTPO Controls* Cases* OR (CI95) Cases* OR (CI95) Cases* OR (CI95)
2 0.14 20/1210 10/436 1.4 (0.6 to 3.0) 1/70 1.0 (0.1 to 7.4) 1/29 2.0 (0.2 to 16.8)
5 0.22 61/1169 27/419 1.2 (0.8 to 2.0) 2/69 0.6 (0.1 to 2.3) 2/28 1.4 (0.3 to 6.7)
10 0.29 115/1115 46/400 1.1 (0.8 to 1.6) 3/68 0.5 (0.1 to 1.5) 2/28 0.7 (0.2 to 3.2)
90 22.62 123/1107 43/403 1.0 (0.7 to 1.4) 6/65 0.8 (0.3 to 1.9) 2/28 0.6 (0.1 to 2.7)
95 127.35 61/1169 23/423 1.0 (0.6 to 1.7) 2/69 0.5 (0.1 to 2.3) 2/28 1.4 (0.3 to 5.9)
98 458.44 24/1206 10/436 1.1 (0.5 to 2.4) 1/70 0.7 (0.1 to 5.4) 1/29 1.7 (0.2 to 13.1)
P ind            
confi                  
<0.5                  
the n               



























than one year fr








d draw and TTE
wer percentiles
red to numbers
Table              
for age    
5: Odds rati
, sex and BM
os for per
I).
centiles of FT4 and provoked or unprovoked cases (adjusted
Provoked Unprovoked
P FT4 (pmol/l) Cases* Controls* OR (CI95) Cases* Controls* OR (CI95)
2 10.7 5/233 21/1210 1.2 (0.4 to 3.2) 5/203 21/1210 1.5 (0.7 to 3.6)
5 11.1 7/231 54/1177 0.7 (0.3 to 1.5) 15/193 54/1177 1.5 (0.8 to 2.9)
10 11.6 27/211 122/1109 1.2 (0.7 to 1.8) 32/176 122/1109 1.5 (1.0 to 2.3)
90 15.3 31/207 120/1111 1.5 (1.0 to 2.4) 24/184 120/1111 1.4 (0.9 to 2.3)
95 16.0 18/220 58/1173 1.9 (1.0 to 3.3) 12/196 58/1173 1.5 (0.8 to 3.0)
98 16.9 10/228 24/1207 2.6 (1.1 to 5.8) 7/201 24/1207 2.5 (1.0 to 6.2)
P indic               
the low               












; OR, odds ratio













Table 6:       Incidence rates for higher levels of FT4





90 65215 341853 all 55 391 1.6 (1.2 to 2.1) 1.3 (1.2 to 1.4)
95 65215 341853 all 30 416 1.8 (1.2 to 2.5) 1.3 (1.2 to 1.4)
98 65215 341853 all 17 429 2.5 (1.4 to 4.0) 1.3 (1.2 to 1.4)
90 65215 65215 1 14 57 2.1 (1.2 to 3.6) 1.0 (0.7 to 1.3)
95 65215 65215 1 9 62 2.8 (1.3 to 5.2) 1.0 (0.8 to 1.3)
98 65215 65215 1 5 66 3.8 (1.2 to 8.9) 1.0 (0.8 to 1.3)
90 65215 32608 0.5 6 24 1.8 (0.7 to 4.0) 0.8 (0.5 to 1.2)
95 65215 32608 0.5 5 25 3.1 (1.0 to 7.2) 0.8 (0.5 to 1.2)
98 65215 32608 0.5 4 26 6.1 (1.7 to 15.7) 0.8 (0.5 to 1.2)
P indica              














High levels of procoagulant factors mediate the 


















Thyroid hormone affects the coagulation system, but its effect on clinical disease is 
not clear. We determined the associations between levels of free thyroxine (FT4), 
thyroid stimulating hormone (TSH) and thyroid peroxidase antibodies (antiTPO) with 
levels of coagulation factors and the risk of venous thrombosis.
Methods
In a large population based case-control study (MEGA-study) into the etiology of 
venous thrombosis we determined levels of FT4, TSH and antiTPO and coagulation 
factors FII, FVII, FVIII, FIX, FX, VWF, antithrombin, protein C and S, and fibrinogen 
in 2177 cases and 2826 controls. 
Results
High levels of FT4 were associated with increased concentrations  of procoagulant 
factors, and not with levels  of the anticoagulant factors. High levels of FT4 were also 
associated with the risk of venous thrombosis, up to an OR of 2.2 (CI95 1.0-4.6) for 
levels  above 24.4 pmol/l relative to FT4 levels between 15.5 and 18.9 pmol/l. In 11 
cases and 1 control clinical hyperthyroidism had been diagnosed within a year of the 
thrombotic event, leading to an OR of 17.0 (CI95 2.2-133.0) for thrombosis. The 
odds ratios  approached unity after adjustment for FVIII and VWF, which suggests 
that the effect was mediated by these factors. Low TSH levels were also, but less 
evidently associated with thrombosis, while there was no association with antiTPO 
and venous thrombosis risk.  
Conclusions
High levels of FT4 increase the concentrations of procoagulant proteins FVIII, FIX, 





As early as  1913, a case-report suggested a relationship between thyroid disease 
and venous  thrombosis [13,23]. This and subsequent case-reports described 
subjects with hyperthyroidism and rare types of venous thrombosis, such as cerebral 
venous thrombosis [14-18]. Later studies focused on alterations  in coagulation 
factors in patients  with thyroid disease and most confirmed that hyperthyroidism was 
associated with prothrombotic changes. These included a rise in several individual 
coagulation factors, with most consistent effects on levels of factor VIII (FVIII), von 
Willebrand factor (VWF) and fibrinogen [19,22,25,32-34]. However, studies 
assessing the effect of high levels of FT4 on the occurrence of venous thrombosis 
are scarce. In a recent case-control study a 2-fold increased risk for venous 
thrombosis  was found for a free thyroxine (FT4) level above 17 pmol/L compared 
with a FT4 below this level, where relative risks increased with higher levels of FT4 
[42]. Furthermore, in a case-cohort study performed within the HUNT2 cohort in 
Norway, the risk of venous thrombosis  clearly increased gradually with increasing 
levels  of FT4 (up to a 10-fold increased risk for FT4 levels >17.3 pmol/l relative to 
levels  below this  cut-off) [48]. The sample sizes of these studies allowed establishing 
the relation between FT4 and venous thrombosis, but no in depth analysis  was 
possible. Also, no citrated blood was available for analysis of coagulation factors. 
While the associations with venous thrombosis  risk in these studies, and with 
procoagulant factors in other studies suggest a mechanism for the prothrombotic 
effect of high levels of FT4, no studies have assessed both in a single sample, and 
hence no formal mediation analysis has been performed.
The aim of the current analysis was therefore to study in a large population-based 
case-control study the effect of thyroid hormone levels  on levels  of coagulation 
proteins and to assess the role of the latter in the association between FT4 and 
venous thrombosis.
Methods
The Multiple Environmental and Genetic Assessment of risk factors  for venous 
thrombosis  (MEGA) study is a large population-based case-control study. Data 
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collection and ascertainment of venous thrombotic events  have been previously 
described in detail [4]. Briefly, patients  aged 18 to 70 years and diagnosed with a first 
deep venous thrombosis  (DVT) of the leg, a pulmonary embolism (PE) or a 
combination of both were asked to participate in the study. Patients were recruited 
between 1999 and 2004 from six regional Anticoagulation Clinics in the Netherlands, 
which all are sole providers in a well-defined geographical region. Partners of these 
patients and subjects recruited by Random Digit Dialling (RDD), frequency-matched 
for age and sex, were invited as control subjects. For both control-groups the same 
selection criteria as for patients were applied. The Medical Ethics Committee of the 
Leiden University Medical Center approved the study protocol. Written consent was 
obtained from all participants. 
Of 6237 eligible patients with DVT and PE, 276 died before they could be included in 
the study. Of the remaining patients 4958 (83%) participated. Information regarding 
the diagnostic procedure was obtained via hospital records and general practitioners. 
Deep venous thrombosis  (DVT) was considered definite when (Doppler) 
ultrasonography showed the presence of a thrombus in the deep veins. Pulmonary 
embolism was considered definite when confirmed with a high-probability ventilation-
perfusion scan, positive spiral computed tomographic findings, or positive 
angiographic findings. Pulmonary embolism was considered probable when the 
diagnosis  was based on a low- or intermediate-probability ventilation-perfusion scan, 
inconclusive spiral computed tomographic findings, or inconclusive angiographic 
findings. In all patients the diagnosis was considered definite or probable [72]. 
Of the 4958 participating patients, 3581 had an eligible partner of whom 2917 
participated (81%). An additional 314 control subjects were included of whom the 
partner (case) was excluded for several reasons  (non-Dutch speaking, severe 
psychiatric disorders), resulting in a total of 3231 partners. Of 4350 eligible RDD 
control subjects, 3000 participated (69%), for a total of 6231 controls. For patients 
and their partner controls, the date of the thrombotic event was used as the index 
date. For the RDD controls the date of completion of the questionnaire was used as 
index date. Participants were asked to complete a questionnaire on potential risk 
factors for venous thrombosis (including thyroid disease and thyroid medication) and 
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to donate a venous  blood sample after an overnight fast. Blood was donated with a 
median of 10 months after the event (range: 3 to 36 months). Only when a 
participant was still using oral anticoagulant treatment with vitamin K antagonists 
more than one year after the index date, the blood sample was drawn during 
anticoagulant treatment. For logistic reasons, blood sampling was  performed for 
patients included up to June 2002; after this  date only DNA was collected via buccal 
swabs.
For the present analysis, participants  with a history of cancer were excluded 
because of the effect of cancer on the coagulation system [4], leaving  a total of 7717 
remaining participants (2775 patients and 4942 controls). Participants  who provided 
a positive answer to the question “did you have any thyroid disease in the past 12 
months” or indicated use of thyroid related medication in the questionnaire (n=310) 
within one year from the index date received a second questionnaire requesting 
details  about type and time of diagnosis  of thyroid disease. These diagnoses were 
checked with the general practitioner.
Blood samples were drawn into vacuum tubes containing 0.1 volume 0.106 mol/l 
trisodium citrate as anticoagulant. Cells  and plasma were separated by 
centrifugation. Plasma samples were stored at -80°C. A blood sample was available 
in 2179 patients. In 2177 of these samples FT4 and antiTPO could be measured; 
TSH was measured in 2142 samples. A total of 2826 blood samples were available 
from the controls. Levels of free thyroxine (FT4) could be assessed in 2826 samples, 
thyroid stimulating hormone (TSH) in 2769 samples, and anti-thyroid peroxidase 
antibodies (antiTPO) in 2820 samples of control subjects. Levels  of FT4, TSH and 
antiTPO were measured in citrated plasma using commercially available assays 
(ADVIA Centaur® immunoassay system, Siemens Healthcare Diagnostics, Marburg, 
Germany). As these tests have not been validated by the manufacturer for use with 
citrated plasma, a serum/citrated plasma study was performed to characterize the 
difference. Systematic differences  were small and linear regression analysis showed 
a strong association between serum and plasma levels for all thyroid hormones 
(regression coefficients: β≥0.92) [42]. From this analysis  we recalibrated FT4 levels 
(correction factor 1.11). Concentrations of factor II, VII, VIII, X, XI, protein S and 
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antithrombin were measured as activity levels with a mechanical clot detection 
method on a STA-R coagulation analyzer (Roche Diagnostics, Almere, the 
Netherlands). All measurements were performed following the instructions of the 
manufacturer (Diagnostica Stago, Asnières, France). Levels  of factor IX antigen were 
determined by enzyme-linked immunosorbent essay (ELISA). Von Willebrand factor 
antigen was measured with the immuno-turbidimetric method, using the STA liatest 
kit (rabbit anti human von Willebrand factor antibodies (Diagnostica Stago, Asnières, 
France)). Fibrinogen activity was measured on the STA-R analyzer according to the 
method of Clauss. Protein C was measured with a STA-R chomogen kit (Diagnostica 
Stago, Asnières, France). All tests were performed by technicians who were unaware 
of the status of the sample (i.e. whether it was from a case patient or control 
subject).
General characteristics  are reported as medians and their 2.5th to 97.5th percentile or 
as total numbers and proportions (%). We calculated means and their 95% 
confidence intervals (CI95) for each coagulation factor for different FT4 levels 
(FT4<10 pmol/l, FT4=10 to 12, FT4=13 to 15, FT4=16 to 18, FT4=19 to 21, FT4=22 
to 24, FT4>24). For the vitamin K dependent coagulation factors, vitamin K 
antagonist users were excluded from the analyses (n=31). 
FT4 levels in citrate were only provided by the laboratory in rounded numbers, 
without decimals. Therefore, using percentiles  was not possible, as there were too 
many subjects with the same FT4 level. Practically, a citrated FT4 level of 14 pmol/L 
can be read as all FT4 levels between 13.5 and 14.5 pmol/L. Citrated FT4 levels of 
14 to 17 pmol/l (corresponding to serum FT4 15.5 to 18.9 pmol/l) were chosen as 
reference group, as this  range consisted of about 60 % in the controls, and 
contrasted to citrated FT4 levels of 18, 19, 20, 21 and >22 pmol/l (respectively 
corresponding to serum FT4 20.0; 21.1; 22.2; 23.3 and >24.4 pmol/l). For TSH and 
AntiTPO (which results were provided in decimals) we determined percentiles for the 
distribution within the control subjects. For TSH and AntiTPO, participants with levels 
between the 20th to the 80th percentile of values within the controls constituted the 
reference category. TSH levels between the 10th and 5th, 5th and 2.5th, 1st to 2.5th, 
0.5th to 1st and <0.5th percentile were compared with the reference category. For 
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AntiTPO, levels between the 80th and 90th, 90th and 95th, 85th and 97.5th 97.5th and 
99th and >99th percentile were compared against the reference category. Laboratory 
values in patients diagnosed with hyperthyroidism between the thrombotic event and 
the blood draw will have been affected by treatment. Therefore, to study the effect of 
overt hyperthyroidism, patients with diagnosed hyperthyroidism at the time of the 
thrombotic event or FT4 levels  >24pmol/l were combined and compared with those 
with normal laboratory values. Logistic regression was used to calculate odds ratios 
and their 95% confidence intervals. All analyses were adjusted for age and sex, in a 
conventional logistic model, to take the frequency matching into account. Adjustment 
for body mass index (BMI) and smoking was added because of the effect of BMI and 
smoking on both FT4 and on thrombosis. For body mass index, adjustment was 
made categorically (BMI: BMI<25 kg/m2; BMI between 25 kg/m2 and 30 kg/m2; BMI >30 
kg/m2), and smokers were classified as current/former smoker and non-smoker. A 
restricted analysis with only the cases in whom blood was sampled within 6 months 
after the thrombotic event was performed to minimize the effect of natural variation in 
hormone levels over time.
To assess mediation of the relation between FT4 and venous thrombosis via 
coagulation factors found to be related to FT4 levels, the odds ratios  were 
additionally adjusted for the levels  of these factors. To assess whether there was a 
difference in risk for venous thrombosis  in types of thrombosis, analyses were split 
for DVT and PE patients. In the group with pulmonary embolism, patients  with and 
without concurrent deep venous thrombosis were included. For the analysis of 
provoked thrombosis, patients  were included who had had surgery, plaster cast, who 
were bed ridden for more than 4 days, who had a minor injury, were pregnant or 
used oral contraceptives or hormone replacement therapy with estrogens  within one 
year before the thrombosis. Unprovoked thrombosis was defined as absence of the 
aforementioned factors. Statistical analyses were performed with statistical package 
SPSS 17.0 for OsX (SPSS Inc, Chicago, IL, USA). 
Results
Table 1 shows the general characteristics of the 2177 case patients and the 2826 
control subjects. The age of the participants ranged from 18 to 70 years with a 
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median of 49.3 years in the cases and a median of 49.9 years in the controls. 
Median level of FT4 was 16.6 pmol/l (P2.5 to P97.5: 12.2 to 21.1), median TSH level 
was 1.22 mU/l (P2.5 to P97.5: 0.35 to 4.06) and median antiTPO level was 16.7 U/ml 
(P2.5 to P97.5: 16.7 to 1444.4), all in controls. Levothyroxine was used by 47 cases 
(2.2%) and 86 controls (3.0%). Thyreostatic drugs were used by 9 cases (0.4%) and 
7 controls  (0.2%). 35 cases (1.6%) and 33 controls (1.2%) had overt 
hyperthyroidism, either based on levels exceeding 24 pmol/l (16 cases, 12 controls) 
or on a previous clinical diagnosis (19 cases, 21 controls)  
A rise in mean level of FVIII, FIX, fibrinogen and VWF was observed with increasing 
FT4 levels  in the control subjects (Figure 1). In controls with a FT4 <10 pmol/L mean 
VWF level was 111 U/dL (CI95 78 to 143) which gradually rose towards  a mean VWF 
level of 178 U/dL (CI95 140 to 215) for FT4>24 pmol/L. FVIII activity also rose 
gradually from 110 U/dL (CI95 86 to 133) for FT4 levels of <10 pmol/L towards 154 
U/dL (CI95 129 to 179) for FT4>24 pmol/L. FVIII antigen levels rose from 120 U/dl 
(CI95 87 to 154) at FT4 levels  <10pmol/L towards 176 U/dL (CI95 146 to 207) for 
FT4>24 pmol/L. At a FT4 level <10 pmol/L the mean FIX level was 99 U/dl (CI95 84 
to 113), whereas a mean FIX level of 121 U/dL (CI95 114 to 128) was found for FT4 
levels  >24 pmol/L. Fibrinogen levels were equal at the lowest and highest FT4 levels 
(3.8 g/L (CI95 3.3 to 4.2) and 3.7 g/L (CI95 3.4 to 4.0) respectively), while they were 
lower in between. No clear associations were observed between FT4 levels and 
concentrations of prothrombin, VII, X, XI, antithrombin, protein C or protein S (data 
not shown). 
Individuals  with the highest FT4 levels  (over 24.4 pmol/l) had a two-fold increased 
risk of thrombosis, relative to those with levels in the reference category of less than 
18.9 pmol/l (OR 2.2, CI95 1.0-4.6, adjusted for age, sex, BMI and smoking). When 
the analysis was restricted to cases in whom blood samples were taken within 6 
months after the thrombosis (282 cases), the association was somewhat stronger, 
with an odds ratio of 2.6 (CI95 0.7 to 9.6) for FT4 of >24.4 pmol/L. The odds ratios 
increased gradually with FT4 levels  between the reference category and the highest 
levels  (Table 2). Those with a history of ever hyperthyroidism had a 1.6-fold 
increased risk of venous thrombosis (CI95 1.0 to 2.8). When only subjects were 
included in whom this was established, by clinical diagnosis or blood draw, less than 
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one year before or shortly after the index date, an odds ratio of 17.0 (CI95 2.2 to 
133.0) was found. The relation between TSH and the risk of venous thrombosis was 
inverse to that of FT4, but less pronounced. No clear association was observed 
between levels of antiTPO and risk of venous thrombosis (Table 2).
The association between FT4 levels and venous thrombosis  was present for both 
deep venous thrombosis and pulmonary embolism, although slightly stronger for the 
former, with an odds  ratio of 2.7 (CI95 1.2 to 6.1) for DVT and 1.5 (CI95 0.5 to 4.5) 
for PE, for FT4 levels >24.4 pmol/L (Table 3). High FT4 levels were associated with a 
doubling of the risk of provoked thrombosis, with an OR of 2.0 (CI95 0.9 to 4.7) for 
FT4 > 24 pmol/L, and a 2.8-fold increased risk of unprovoked thrombosis (CI95 0.8 
to 9.4) (Table 3). Since FT4 appeared to have a clear effect on levels of FVIII, VWF, 
FIX and fibrinogen, an adjustment for these factors was made in the analysis. 
Adjustment for FVIII and VWF (besides age, sex, BMI and smoking) led to an 
attenuation of odds ratios:  at a FT4 level >24.4 pmol/L the OR went from 2.2 (CI95 
1.0 to 4.6) to 1.2 (CI95 0.5 to 3.0). This attenuation was not seen when we adjusted 
for levels of FIX or fibrinogen. Because ABO blood group is a determinant of both 
FVIII/VWF and venous thrombosis, additional adjustment was made for ABO blood 
group (in addition to age, sex, BMI and smoking), which did not lead to any 
substantial changes in the results (data not shown).
Discussion
We studied the relation between thyroid hormones and venous thrombosis in a large 
population-based case-control study with approximately 2000 patients and 3000 
controls. The risk of thrombosis was two-fold increased for individuals with the 
highest levels  of FT4 (>24 pmol/l) compared with those with average values. Those 
with either clinical or biochemical diagnosis of hyperthyroidism shortly before the 
event had a 17-fold increased risk of thrombosis. Increased levels  of FT4 led to 
concomitant increases in several procoagulant factors, notably VWF and FVIII, which 
appeared to fully explain the effect on thrombosis risk.
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These findings are in line with previous studies on separate components of this 
causal pathway: For the first part, the relation between FT4 and procoagulant 
factors, several studies (including experimental ones) showed a shift in the direction 
of a prothrombotic state (mainly elevated levels of factor VIII and von Willebrand 
factor) [21,22,32,42,46-48,73]. For the second part, the causal effect of factor VIII 
and von Willebrand factor on risk of venous thrombosis, several studies show 
evidence, of which the strongest is the effect of ABO blood group, which is a genetic, 
and therefore unconfounded determinant of elevated VWF and FVIII levels and 
which increases (for non-0 groups) the risk of venous thrombosis about 1.5-fold 
[74-76]. Another indication that factor VIII is causally related to venous thrombosis 
risk is that patients with haemophilia A or von Willebrand disease (i.e. with low levels 
of factor FVIII), have a low thrombosis risk [77]. 
 Three previous studies on the relation between FT4 and venous thrombosis 
also reported an elevated risk with high levels of FT4 [42,48,49] with a relative risk of 
10 for FT4 levels of approximately 24 pmol/L measured less than 6 months before 
thrombosis. The latter finding is  in line with the present study where an OR of 17 was 
found for overt hyperthyroidism. 
There are several potential limitations to this study. First, clinical hyperthyroidism 
present at time of thrombosis could have been discovered and treated between the 
time of thrombosis and time of blood sampling (which was the case, as far as we 
know, in at least eight of our clinical cases, in six of whom FT4 levels were 
normalized at the time of blood sampling). This  limitation would result in a 
misclassification leading to underestimation of the risk estimates. This explains why 
risk estimates are lower in this  analysis than in a previous prospective study where 
blood sampling had taken place before the event [48]. Secondly, the case-control 
design of the MEGA study enabled us to explore mechanistic relationships  between 
FT4 and venous  thrombosis, via different coagulation factors. A drawback of this 
design is  that we cannot explain in detail how high levels of FT4 lead to increased 
levels  of FVIII and vWF. For this, experimental studies are required. Thirdly, although 
the MEGA study is a large case control study, the estimates at high FT4 levels were 
still rather imprecise, particularly in subgroups. However, our findings are in line with 
the literature and the dose-response relationship also supports accurate findings. 
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Fourthly, the FT4 levels measured after the thrombosis may not reflect FT4 levels at 
time of the event. However, as these are stable over time [64,65] it is likely that they 
are representative for those at the time of the event. Prolonged storage at -80 (as 
was used in the MEGA-study) does not substantially affect levels of factor VIII or von 
Willebrand factor [78]. Even if it would, such changes would result in random 
misclassification, underestimating the true effect.
How thyroxine influences the coagulation system is not well known. The effect has 
been linked to autoimmune processes and to a direct effect of thyroid hormone on 
gene transcription in the liver and endothelial cells  [36,66,69,70,79,80]. In vitro 
studies have shown a direct effect of tri-iodothyronine (T3), the active form of thyroid 
hormone, on hepatocytes and endothelial cells causing an up-regulation of 
fibrinogen, factor II, factor X, von Willebrand factor and plasminogen [36,66,69]. This 
would support the hypothesis of a direct effect on coagulation gene transcription by 
thyroid hormone. Recently Hooper et al. focused on the influence of thyroxine on 
fibrin formation. Clots  proved to be denser and resistant to fibrinolysis in hyperthyroid 
patients. They suggested that, partially, this relation could be mediated by an 
inflammation response [81]. Although the present study did not focus primarily on the 
pathophysiology of thyroid hormone induced thrombosis, the negative finding of risk 
modification by the presence of anti-thyroid peroxidase antibodies disagrees with the 
hypothesis of this specific autoimmune effect. The positive association between FVIII 
and VWF with levels of FT4 as well as the attenuation of the effect when adjusting 
for FVIII and VWF points toward an effect of FT4 on FVIII and VWF production or 
clearance. Whilst both FVIII/VWF and venous thrombosis  are influenced by ABO 
blood group, adjustment for ABO blood group did not influence the results in our 
study.  
What are the clinical implications of these findings? Most of the cut-off FT4 levels  in 
the present study are within levels of FT4 that will be left untreated in clinical 
practice. Findings of these FT4 levels would in itself have no clinical consequences, 
but could be used in constructing an overall risk profile. For overt hyperthyroidism a 
17-fold risk increase was found. Based on our and the above mentioned previous 
findings in three other studies [42,48,49], routine testing for hyperthyroidism of 
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patients with an unprovoked thrombosis  may be considered, as the diagnosis is not 
always obvious clinically and testing is easily done and relatively cheap. A positive 
result will have a strong impact for the patient because an undetected condition can 
be treated.
Overall, this study provides further insights in the association between thyroid 
hormone and venous thrombosis. A gradually increasing risk of venous thrombosis 
for increasing levels  of FT4 was found, which appeared to be mediated by levels of 
FVIII and VWF. The underlying mechanism and clinical implications of these findings 
should be further explored in future studies.
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Table 1. Characteristics of patients with venous thrombosis and control subjects  
 Cases (n=2177) Controls (n=2826)
Male, n (%) 987 (45.3) 1352 (47.8)
Age at blood sampling, years, median (P2.5 
to P97.5)
48.2 (23.3 to 69.4) 48.7 (23.7 to 68.8)
BMI, kg/m2, median, (P2.5 to P97.5) 26.3 (19.4 to 38.8) 24.9 (19.1 to 35.0)
DVT, n (%) 1283 (58.9)
PE, n (%) 894 (41.1)
Blood sampling within 6 months from VT, n, %260 (11.9)
Operation, n (%) 425 (19.5) 181 (6.4)
Plaster cast immobilisation, n (%) 129 (5.9) 35 (1.2)
Bed immobilization at home, n (%) 369 (16.9) 222 (7.9)
Bed immobilisation in hospital, n (%) 447 (20.5) 214 (7.6)
Minor sportsinjury, n (%) 520 (23.9) 429 (15.2)
Pregnany, n (%) 103 (4.7) 36 (1.2)
Oral contraceptives, n (%) 662 (30.4) 323 (11.4)
Hormone replacement therapy, n (%) 61 (2.8) 81 (2.9)
N indicates number; P, percentile; BMI, body mass index; DVT, deep venous thrombosis; PE, pulmonary 




Table 2. Risk of           
antiTPO.
venous thrombosis associated with different percentiles of FT4, TSH and
FT4 (pmol/L) Controls Cases OR (CI95) Cases* OR* (CI95)
15.5 to 18.9 1844 1346 ref 196 Ref
20.0 135 108 1.2 (0.9 to 1.6) 11 0.9 (0.5 to 1.6)
21.1 44 44 1.5 (0.9 to 2.2) 5 1.2 (0.5 to 3.1)
22.2 20 25 1.8 (1.0 to 3.3) 3 1.3 (0.4 to 4.7)
23.3 8 7 1.3 (0.5 to 3.9) 1 1.3 (0.2 to 11.1)
>24.4 12 16 2.2 (1.0 to 4.6) 3 2.6 (0.7 to 9.6)
TSH (mU/L) Controls Cases OR (CI95) Cases* OR* (CI95)
0.79 to 1.89 1648 1217 ref 152 ref
<0.14 0 0 na 0 na
0.14 to 0.24 27 31 1.5 (0.9 to 2.6) 5 2.1 (0.8 to 5.6)
0.24 to 0.39 42 42 1.3 (0.8 to 2.0) 6 1.6 (0.7 to 3.9)
0.39 to 0.47 69 49 0.9 (0.6 to 1.3) 4 0.6 (0.2 to 1.8)
0.47 to 0.60 132 95 1.0 (0.7 to 1.3) 16 1.3 (0.7 to 2.2)
Anti-TPO (U/mL) Controls Cases OR (CI95) Cases* OR* (CI95)
18.9 to 41.1 2257 1696 Ref 216 ref
41.1 to 159.1 281 255 1.2 (1.0 to 1.5) 40 1.5 (1.0 to 2.2)
159.1 to 361.2 141 124 1.1 (0.9 to 1.5) 17 1.1 (0.7 to 2.0)
361.2 to 554.6 24 26 1.5 (0.8 to 2.7) 1 0.5 (0.1 to 3.4)
554.6 to 804.9 0 0 Na 0 na
P indicates percen           
peroxidise antibod              
restricted analysis f          









; TSH, thyroid stimu
CI, 95% confidence







Table 3. Risk of ven         
percentiles of FT4.
ous thrombosis for different subgroups associated with different
DVT PE
FT4 (pmol/L) Controls Cases OR2 (CI95) Cases OR2 (CI95)
15.5 to 18.9 1844 809 ref 537 Ref
20.0 135 63 1.2 (0.9 to 1.6) 45 1.2 (0.9 to 1.8)
21.1 44 30 1.7 (1.0 to 2.8) 14 1.1 (0.6 to 2.1)
22.2 20 10 1.2 (0.6 to 2.6) 15 2.5 (1.2 to 5.1)
23.3 8 4 1.3 (0.4 to 6.1) 3 1.3 (0.3 to 5.3)
24.4 12 11 2.7 (1.2 to 6.1) 5 1.5 (0.5 to 4.5)
Provoked Unprokoved
FT4 (pmol/L) Controls Cases OR2 (CI95) Cases OR2 (CI95)
15.5 to 18.9 1844 924 ref 364 Ref
20.0 135 61 1.1 (0.8 to 1.6) 44 1.6 (1.1 to 2.3)
21.1 44 30 1.7 (1.0 to 2.7) 12 1.4 (0.7 to 2.8)
22.2 20 10 1.0 (0.4 to 2.2) 13 3.0 (1.4 to 6.3)
23.3 8 4 1.2 (0.3 to 4.3) 3 2.2 (0.5 to 9.2)




























































Recently a relationship between high levels of free thyroxine and venous thrombosis 
has been established. Low levels of thyroxine have been associated with both a 
decreased and an increased risk for venous thrombosis. The aim of this study was to 
evaluate the risk of venous thrombosis in patients with low levels of free thyroxine. 
 
Methods
In a large population based case-control study (MEGA-study) into the aetiology of 
venous thrombosis we determined levels  of FT4, TSH and antiTPO in 2177 cases 
and 2826 controls and estimated odds ratios  to determine relative risks for different 
levels of these hormones.
 
Results and conclusion
The odds ratio was highest (OR 2.5 (CI95 0.9 to 6.7)) at the lowest FT4 levels (<10.0 
pmol/l) compared with the reference category of 15.5 to 18.9 pmol/l. The odds ratio 
decreased with higher levels  of FT4. Adjustment for BMI, smoking, HsCRP, 
cholesterol, HDL cholesterol, triglycerides and homocysteine levels attenuated the 
risk slightly, indicating involvement of these factors in the relation between low levels 
of thyroxine and venous thrombosis. Our study cannot determine the exact relation 
between hypothyroidism and risk of venous thrombosis  as a protective association 
between low levels of FT4 and venous thrombosis may have been masked by 






The relation between hormones and the coagulation system has been a recent focus 
of interest [19,21,23,42,45,46,48,63,67,71]. Hormones such as cortisol, prolactine 
and thyroxine have been shown to have an influence on the coagulation system 
which also results in clinical events [42,82-85]. Generally, high levels of these 
hormones increase the risk of venous thrombosis [42,48,67,84]. With respect to 
thyroxine (FT4), higher levels are associated with higher levels  of factor VIII (FVIII) 
and von Willebrand factor (VWF) [32-34,46,47]. Other coagulation factors (factor IX, 
fibrinogen) have also been shown to rise with the levels  of thyroxine [67]. With lower 
FT4 levels, a decrease of levels of these coagulation factors has  been described 
[19,34]. In line with this  finding, lower levels  of thyroxine were found to be related to 
an increased risk of major bleeding in patients using vitamin K antagonists (this 
thesis) and to acquired von Willebrand disease [34,45,86]. Theoretically, these 
phenomena could translate in a protective effect on the risk of thrombosis. However, 
the two studies on thyroxine and risk of venous thrombosis that have been published 
thus far show   contradictory results. In the ACT study [42], a linear dose relationship 
was seen for the relationship between thyroxine and thrombosis risk, with a 
protective effect for lower levels  and an increased risk for higher levels of thyroxine. 
In the TROL study [48], the analysis revealed a U-shaped relation with an increased 
risk for thrombosis at both highest and lowest levels of thyroxine. Since these studies 
included 190 and 446 patients with venous thrombosis, of whom only a fraction had 
low levels of thyroid hormone, sample sizes were too small to obtain reliable results. 
To shed more light on these contradictory findings, we assessed in detail the effect of 
low levels of thyroxine on the risk of venous thrombosis in a large case-control study 
designed to study risk factors for venous thrombosis (the MEGA study) [67]. Since 
there is little pathophysiological support for an increased thrombosis risk with lower 
levels  of thyroxine, we hypothesized that low levels of thyroxine would have either no 





The Multiple Environmental and Genetic Assessment of risk factors  for venous 
thrombosis  (MEGA) study is a large population-based case-control study. Data 
collection and ascertainment of venous thrombotic events  have been previously 
described in detail [4,67]. Briefly, patients aged 18 to 70 years and diagnosed with a 
first deep venous thrombosis  (DVT) of the leg, a pulmonary embolism (PE) or a 
combination of both were asked to participate in the study. Patients were recruited 
between 1999 and 2004 from six regional Anticoagulation Clinics in the Netherlands, 
which all are sole providers in a well-defined geographical region. Partners of these 
patients and subjects recruited by Random Digit Dialling (RDD), frequency-matched 
for age and sex, were invited as control subjects. For both control-groups the same 
selection criteria as for patients  were applied. During the first half of the inclusion 
period venepunctures were performed to obtain plasma and DNA, while in the 
second half DNA was obtained from buccal swabs. For the present analysis, 
participants with a history of cancer were excluded because of the effect of cancer 
on the coagulation system [4] (2775 cases and 4942 controls remaining). Blood 
samples were available in 2179 cases. In 2177 of these samples  FT4 was 
measured. In 2826 controls FT4 levels  could be measured. Levels of FT4 and TSH 
were measured in citrated plasma using commercially available assays (ADVIA 
Centaur® immunoassay system, Siemens Healthcare Diagnostics, Marburg, 
Germany). As these tests have not been validated by the manufacturer for use with 
citrated plasma, serum/citrated plasma studies were performed for validation [42]. 
Systematic differences were small and linear regression analysis  showed a strong 
correlation between serum and plasma levels for all thyroid hormones (regression 
coefficients: β≥0.92. Therefore all citrated FT4 values are multiplied by 10/9 for 
correction in this study). The Medical Ethics Committee of the Leiden University 




For patients and their partner controls, the date of the thrombotic event was used as 
the index date. For the random digit dialing controls the date of completion of the 
questionnaire was used as index date. FT4 levels were only provided by the 
laboratory in round numbers. Therefore, analyzing the results using percentiles 
would have required arbitrary choices when establishing percentiles. We chose FT4 
levels  of 15.5 to 18.9 pmol/l as reference group and compared them to levels  of 
14.4, 13.3, 12.2, 11.1 and <10.0 pmol/l. For TSH, we used the 20th to the 80th 
percentile as reference category. Further categories were made of the 90th to the 
95th percentile, the 95th to the 97.5th percentile, the 97.5th to the 99th percentile, 
the 99th to the 99.5th percentile and higher than the 99.5th percentile. We used 
logistic regression to calculate odds ratios and their 95% confidence intervals. All 
analyses were adjusted for age and sex, to take the frequency matching into 
account. Furthermore, we adjusted categorically for body mass index (BMI: BMI<25 
kg/m2;  BMI between 25 kg/m2 and 30 kg/m2; BMI >30 kg/m2) and smoking status 
(current smoker vs  former smoker or never smoker). High sensitivity CRP (HsCRP), 
triglyceride, cholesterol, high density lipid (HDL) cholesterol and homocysteine 
plasma concentrations were added as continuous variables. Statistical analyses 
were performed with statistical package SPSS 17.0 for OsX (SPSS Inc, Chicago, IL, 
USA).
Results and Discussion
A total of 2177 patients and 2826 control subjects were included in the analysis. 
Blood samples were collected with a median of 10 months after the event (range 3 to 
36 months).
As shown in Table 1, we found an increase in the risk of venous thrombosis  for levels 
of FT4 below 13.3 pmol/l, compared with the reference category of 15.5 to 18.9 
pmol/l. The odds  ratio was highest (OR 2.5 (CI95 0.9 to 6.7)) at the lowest FT4 levels 
(<10.0 pmol/l) compared with the reference category. Given the negative feedback of 
FT4 on TSH, it is expected that increased levels  of TSH give similar risk estimates 
as reduced levels of FT4. This was indeed observed (see Table 2). In general, the 
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odds ratios  increased with increasing TSH levels. ORs of 1.8 (CI95 0.9 to 3.5) were 
found for TSH levels from 5.54 to 8.96 mU/ml as well as for TSH > 8.97 mU/ml (OR 
1.8 (CI95 0.8 to 3.6)). Additional adjustment for BMI, smoking, HsCRP, cholesterol, 
HDL cholesterol, triglycerides and homocysteine levels attenuated the risk slightly, 
especially in the FT4 analysis, indicating involvement of these factors in the relation 
between low levels of thyroxine and venous thrombosis.
As an increased risk of venous thrombosis at the hypothyroid end of the spectrum is 
difficult to explain pathophysiologically, how can our findings of an increased risk be 
understood? A first option is that this is due to chance, which is plausible, 
considering the rather wide confidence intervals. However, it seems unlikely that 
chance would reverse a truly protective effect. Alternatively, our findings can be 
explained by confounding, although we adjusted for putative confounders such as 
age, sex, BMI, and smoking. Several studies have described an association between 
hypothyroidism and cardiovascular risk factors, such as obesity, LDL cholesterol, 
hyperhomocysteinemia and endothelial dysfunction; hypothyroidism has also been 
associated with increases in diastolic blood pressure and C-reactive protein 
[59,60,62,63]. Recent studies have also suggested that some of these arterial 
cardiovascular risk factors are associated with an increased risk of venous 
thrombosis  [87-89]. Adjustment for these factors led to some attenuation of the ORs, 
indicating a pathway between hypothyroidism and thrombosis via these factors. 
Another possibility is  misclassification of the thyroid hormone measurements, i.e., 
that the measured FT4 levels did not reflect the actual levels at the time of the event. 
Although levels of FT4 generally do not tend to fluctuate very much [64,65], it is not 
unthinkable that at the time of the thrombosis high FT4 levels were present, caused 
by some form of thyroid disease, which levels, due to treatment or natural course of 
this  condition dropped to low FT4 levels  at the time of blood sampling, leading to a 
spurious association between low levels and risk of  thrombosis.  
Other studies  reported low risks at the hypothyroid end of the spectrum depending 
on time of blood sampling. In the TROL study [48], the odds ratio for the lowest FT4 
category (<10.7) was 1.3 (CI95 0.6 to 2.8). However, this  OR decreased to  0.8 
(CI95 0.1 to 6.0) when the analysis was  restricted to cases in whom blood was 
drawn within 6 months before the thrombosis. In the ACT study [42], where blood 
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was sampled at the time of presentation of the event, a protective effect for low 
levels  of FT4 was also  seen up to a 10-fold protective effect for FT4 levels <12 
pmol/L. Both studies indicate that blood sampling close to the event is  associated 
with a protective effect of low levels  of FT4, while this reverses with increasing time 
between sampling and the event.
Putting the information of these studies and our results together, we would propose 
the following relation between hypothyroidism and venous thrombosis: 
hypothyroidism is in its acute phase associated with a decreased risk of venous 
thrombosis. However, as  hypothyroidism is also linked with some cardiovascular risk 
factors which in their turn are associated with increased risk of venous  thrombosis, 
this  could lead to a non-causal inverse association, i.e., of an increased risk. When 
misclassification in the measurement of FT4 is present, the protective relation 
between hypothyroidism and venous  thrombosis will be obscured by the presence of 
these factors. This  has probably been the case in our study where the median time 
between venous thrombosis and blood sampling was  10 months with a minimum of 3 
months. We therefore conclude that our study cannot determine the exact relation 
between hypothyroidism and risk of venous  thrombosis and that a protective 
association may have been masked by cardiovascular risk factors such as obesity, 
decreased endothelial function and inflammation which are associated with 
decreased thyroid function. Further knowledge on this issue is nevertheless 
important as physicians may find this  of use in hypothyroid patients when they 
encounter  high risk situations, such as a planned surgery. 
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Low levels
Table 1. Risk of        venous thrombosis associated with low levels of FT4
FT4 (pmol/L) Controls Cases OR1 (CI95) OR2 (CI95) OR3(CI95)
15.5 to 18.9 1844 1346 ref ref ref
14.4 454 318 1.0 (0.8 to 1.1) 0.9 (0.8 to 1.1) 0.9 (0.8 to 1.1)
13.3 206 202 1.3 (1.1 to 1.6) 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.6)
12.2 76 72 1.3 (0.9 to 1.8) 1.3 (0.9 to 1.8) 1.2 (0.9 to 1.7)
11.1 21 28 1.8 (1.0 to 3.1) 1.6 (0.9 to 2.8) 1.7 (0.9 to 3.0)
<10.0 6 11 2.5 (0.9 to 6.7) 2.0 (0.7 to 5.7) 1.7 (0.6 to 4.9)
FT4 indicates fr            
category. OR1: o                 
and smoking; O            










age and sex; OR2
ted for age, sex,
cysteine levels.
confidence interval
: odds ratio adjusted
BMI, smoking, Hs
and ref, reference
for age, sex, BMI
CRP, cholesterol,
Table 2.  Risk of       venous thrombosis associated with increased TSH levels
TSH (mU/ml) Controls Cases OR1 (CI95) OR2 (CI95) OR3(CI95)
0.79 to 1.89 1658 1225 ref ref ref
2.42 to 3.00 138 103 1.0 (0.8 to 1.3) 1.0 (0.7 to 1.3) 1.0 (0.7 to 1.3)
3.01 to 4.02 70 77 1.4 (1.0 to 2.0) 1.4 (1.0 to 2.0) 1.4 (1.0 to 2.0)
4.03 to 5.53 41 37 1.2 (0.8 to 1.9) 1.2 (0.8 to 2.0) 1.2 (0.8 to 2.0)
5.54 to 8.96 15 20 1.8 (0.9 to 3.5) 1.7 (0.8 to 3.4) 1.7 (0.8 to 3.5)
>8.97 13 17 1.8 (0.8 to 3.6) 1.5 (0.7 to 3.1) 1.4 (0.7 to 3.0)
TSH, thyroid stim               
p97.5, p97.5 to p9              
* restricted analys               
ratio adjusted for                 
odds ratio adjuste            
and homocysteine 
ulating hor
9, p99 to p
is for blood
age and se








p99.5; OR, odds rat
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High levels of the thyroid hormone thyroxine are associated with an increased risk of 
first venous thrombosis. The risk of recurrent venous thrombosis in relation to 
thyroxine levels has not been studied.
Methods
We performed a nested case-control study in a large cohort of patients with a first 
venous thrombosis (MEGA study), in whom blood samples  were taken some months 
after their first event. Information on recurrent venous thrombosis was retrieved over 
a mean period of 5.8 years. Patients with a recurrence (381 cases) were matched 
(1:2) with patients without a recurrence (761 controls) on time from first venous 
thrombosis  to blood sampling. Odds ratios (OR) and 95% confidence intervals (CI95) 
were calculated for the risk of venous thrombosis for different cut-off points of free 
thyroxine (FT4) levels. A restricted analysis  was performed in subgroups where the 
time between blood sampling and recurrent event was less than 0.5, 1 or 1.5 years.
Results
The risk of recurrent venous thrombosis was not associated with levels of FT4. The 
OR for recurrent venous thrombosis   for FT4 levels <15.5 pmol/l was 0.8 (CI95 
0.6-1.1), relative to FT4 levels of 15.5 to 18.9 pmol/L; for FT4 >24.4 pmol/l the OR 
was 0.6 (CI95 0.1-3.8). Similar odds ratios were found in the restricted analyses. 
Conclusions






While the annual incidence of a first venous thrombosis is approximately 1-2 per 
1000 person-years [3], the recurrence risk of a venous thrombotic event is much 
higher. The cumulative incidence of recurrent venous thrombosis is  4-11% within the 
first year and 12-30% in the five years after the first event, with incidence rates of 
recurrence varying between 25 to 46 per 1000 person-years [7-10].   
Many risk factors for first venous thrombosis are known, but the determinants of 
recurrent venous thrombosis are less clear[8]. Furthermore, the risk profile for 
recurrent venous thrombosis  is different from that of first venous thrombosis. Many 
prothrombotic abnormalities  do not play an important role in the risk of recurrence 
[7,9]. Age, an important risk factor for first venous thrombosis, does not influence risk 
of recurrence [11,12].  
In recent years, the link between endocrine disorders and venous thrombosis  has 
been extensively studied [19,22,42,46,48,83-85,90,91]. High levels of endogenous 
hormones, such as the stress hormone cortisol and thyroid hormone (thyroxine), 
have been found to be associated with an increased risk of venous thrombosis 
[42,83]. One case-control study reported a 2-fold increased risk for venous 
thrombosis  for free thyroxine (FT4) levels above 17 pmol/L compared with a FT4 
level of 15 pmol/L [42]. In another case-cohort study there was a positive relation 
between increasing levels of free thyroxine and risk of venous thrombosis (up to a 
10-fold increased risk for FT4 levels >17.3 pmol/l relative to levels  below this cut-off) 
[48]. Furthermore, a 2.3-fold increased risk for venous thrombosis was seen in 
patients with clinical hyperthyroidism compared to non-thyroid disease patients  [49]. 
The effect of thrombosis  seemed mainly mediated by increased levels of von 
Willeband factor and factor VIII [this thesis].
So far, to our knowledge, the risk of recurrent venous thrombosis  in relation to high 
levels  of thyroxine has not been studied. The aim of our study was therefore to 
investigate the role of thyroid hormones in recurrent venous thrombosis, in a large 





The MEGA-study is  a large population-based case-control study into risk factors for 
a first venous thrombosis. Data collection and ascertainment of venous thrombotic 
events have been previously described in detail [4]. Briefly, patients aged 18 to 70 
years and diagnosed with a first deep venous thrombosis of the leg, a pulmonary 
embolism or a combination of both were asked to participate in the study. Patients 
were recruited between 1999 and 2004 from six regional Anticoagulation Clinics in 
the Netherlands. Blood samples were obtained with a median of 10 months after the 
event. Only when a participant was still using oral anticoagulant treatment with 
vitamin K antagonists more than one year after the index date, the blood sample was 
drawn during anticoagulant treatment. For logistic reasons, blood sampling was 
performed for patients included up to June 2002; after this date only DNA was 
collected via buccal swabs.
Blood samples were available in 2179 patients. In 2177 of these samples  FT4 and 
antiTPO could be measured; TSH was measured in 2142 samples. The Ethics 
Committee of the Leiden University Medical Center approved the study protocol. 
Written consent was obtained from all participants. 
Possible recurrent events were retrieved in two ways. Firstly, from the patients via a 
short questionnaire inquiring about whether a patient had had a recurrent event and 
secondly from the anticoagulation clinics. Questionnaires were sent by mail between 
June 2008 and July 2009. When questionnaires  were not returned, the questions 
were asked by telephone interview [Flinterman, LE et al. submitted for publication]. 
Subsequently, additional information was requested from physicians to adjudicate 
the diagnosis. 
A recurrence was considered certain when a discharge letter was present concluding 
a diagnosis of recurrence. The event should be in a different vein or in a different 
part of the body than the first event. If the location of either the first or second 
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thrombosis  was unclear, an event was still classified as a certain recurrence when at 
least three months had passed since the first thrombosis. An event was also 
classified as certain when a discharge letter was not available but both the 
anticoagulation clinic and the patient reported a recurrence at a clearly different 
location than the first event (contralateral leg, or DVT after PE or vice versa) or when 
a time period of more than a year had passed between the two events. A third option 
was a registered cause of death from pulmonary embolism or venous thrombosis at 
least six months after the first event. 
Laboratory assessments
Blood samples were drawn into vacuum tubes containing 0.1-volume 0.106-mol/l 
trisodium citrate as anticoagulant. The blood sample was separated into plasma and 
cells through centrifugation. Plasma samples were stored at -80°C. We measured 
levels  of FT4, TSH and antiTPO in citrated plasma using commercially available 
assays (ADVIA Centaur® immunoassay system, Siemens Healthcare Diagnostics, 
Marburg, Germany). As these tests have not been validated by the manufacturer for 
use with citrated plasma, serum/citrated plasma studies were performed to 
characterize the correlation [42]. Only small systematic differences were detected 
and linear regression analysis showed a strong association between serum and 
plasma levels for all thyroid hormones (regression coefficients: β≥0.92). The levels  of 
FT4 were returned from the routine laboratory rounded to whole numbers. TSH was 
provided as 2 decimal numbers. The samples were measured before the recurrence 
status of the patients was known. 
 
Statistical analyses
We determined percentiles for the distribution of FT4 and TSH within the control 
subjects. However, as citrated FT4 levels were rounded to whole numbers, the data 
distribution was more categorical than continuous. Therefore the data were analyzed 
with citrated FT4 (CFT4) of 14 to 17 pmol/l as reference category (resembling the 
20th to 80th percentile). This resulted in a reference category of 15.5-18.9 for the 
recalculated plasma FT4 levels which was compared with levels  of FT4 of 20, 21.1, 
22.2, 23.3 and >24.4 pmol/l. A category for a FT4 of < 15.5 pmol/l was also included. 
For TSH the reference category was the 20th to the 80th percentile. These data 
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were further divided in categories containing the 20th to 10th percentile, 10th to 5th 
percentile, 5th to 2.5th percentile, 2.5th to 1st percentile and <1st percentile. 
In the MEGA study, blood was sampled a few months after the first venous 
thrombosis. Since thyroid disease can develop relatively acutely and is a treatable 
disease, levels of FT4 are likely to change over time and so the risks  will similarly 
vary. Furthermore, the timing of the measurement differed between patients (i.e., a 
median of 10 months after the first event (range: 6 to 21)), as well as  the duration of 
the subsequent follow-up. To better take these variations into account, we decided to 
use a nested case-control design. All patients  with a certain recurrence (cases) were 
matched with patients  without a recurrence (controls), in a 1:2 ratio, first of all on 
time from first venous thrombosis to blood sampling; furthermore, controls had to be 
recurrence free at the time their corresponding case had a recurrence. This way both 
cases and controls  had the same exposure duration and the same time (opportunity) 
to develop a recurrent event, and hence the odds ratio can be considered as an 
incidence rate ratio [54]. A conditional logistic regression analysis was performed and 
all analyses  were additionally adjusted for age and sex. Subsequently, analyses 
were performed in subgroups  where the time between blood sampling and recurrent 
event was  restricted to a maximum of 1 and 1.5 years. All matching and analyses 
were performed using R 2.13.1 (R Foundation for Statistical Computing, Vienna, 
Austria) [55-57].
Results 
A total of 2209 patients  with a first venous thrombosis from the MEGA study in whom 
blood samples were available were followed for recurrence [67]. Of these 2209 
patients, 423 (19%) experienced a recurrent thrombosis. With a total follow-up of 16 
021 person-years, this led to an incidence rate of 26.4 (95% CI 24.0-29.0) events per 
1000 person-years. Median follow up time was 1128 days (3 years) for the patients 
with recurrence and 2976 days (8 years) for the patients without. In 381 of the 423 
recurrence cases, all information needed to perform the matching procedure was 
available. Matching in a 1:2 ratio resulted in 761 patients without a recurrent venous 
thrombosis. Of the 381 cases, FT4 levels had been measured in 343 cases and TSH 
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levels  in 335 cases. The median time from first venous thrombosis to blood sampling 
was 310 days in both groups. Median time from blood sampling to recurrent event or 
end of follow-up was 757 days in patients with recurrent venous thrombosis and 
1725 days in patients  without recurrence (Table 1). Median age distribution was 
almost equal in patients with recurrence as in patients without (Table 1). Of patients 
with recurrent venous thrombosis 236 (62%) were men compared with 332 (44%) of 
patients without recurrence. 
At time of blood sampling, the median FT4 level was 16.7 pmol/l both in patients with 
and without recurrence (p2.5 to p97.5: 12.2 to 21.1 pmol/l for both groups). For TSH, 
the median level was 1.31 mU/l (p2.5 to p97.5: 0.38 to 4.65 mU/l) in the patients with 
recurrent venous thrombosis and 1.36 mU/l (p2.5 to p97.5: 0.35 to 4.77 mU/l) in the 
patients without recurrent venous thrombosis. 
In the matched analysis, the odds ratios (OR) for risk of recurrent thrombosis varied 
between 0.8 (CI95 0.6 to 1.1) for FT4 levels  below 15.5 pmol/l compared with the 
reference category (FT4 levels of 15.5 to 18.9 pmol/l) to an OR of 0.6 (CI95 0.1 to 
3.8) at a cut-off of >24.4 pmol/l. For TSH, the ORs varied between OR: 0.9 (CI95 0.7 
to 1.3) for a cut-off level of >2.03 mU/l and OR 0.4 (CI95 0.1 to 1.8) for a level of 
<0.22 mU/l compared with the reference category of TSH levels of 0.84 to 2.03 mU/l 
(Table 2). An analysis  restricted to cases who had a recurrent venous thrombosis 
within one year after blood sampling and their matched controls, resulted in similar 
risk estimates (Table 3). When time between blood sampling and recurrent 
thrombosis  was extended to 1.5 year, an OR of 0.5 (CI95 0.1 to 3.8) for the highest 
FT4 levels (>24.4 pmol/L) was found. 
An effect of FT4 on recurrence is  expected to be most evident in the group with a 
combination of hyperthyroidism (a FT4>23 pmol/l) at time of blood measurement and 
an unprovoked thrombosis, since their first venous thrombosis is most likely to have 
been caused by elevated levels of FT4. This  was the case in 4 patients. Three of 
these four patients, who all were men, suffered from recurrent venous thrombosis 
(153, 729 and 771 days after the first venous thrombosis) over a total follow-up of 
13.18 person-years, leading to an incidence rate of 227.6 per 1000 person-years 
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(CI95 46.9 to 665.2). One of the three unprovoked patients reported that 
hyperthyroidism had been diagnosed between the first venous thrombosis  and the 
recurrent event. At the time of their first event they had not been classified as 




In line with the pattern observed for many other risk factors for first venous 
thrombosis  (e.g. thrombophilia, age), high levels of FT4, while a risk factor for a first 
event, do not play a major role in the occurrence of recurrent venous thrombosis. 
High levels  of FT4 at the time of blood sampling even seem to decrease the risk of 
recurrence. Similar findings have been reported for other transient risk factors  for a 
first event, such as surgery or plaster cast immobilization [9,92].
As thyroid disease can occur acutely and will be, when treated, of a transient nature, 
the analysis of the relation was not straightforward, particularly since only one blood 
sample between first and recurrent venous thrombosis was available. Several 
scenarios influencing risk calculations could have occurred, either leading to an 
accurate or to an underestimation of the relative risk (Table 4). In some patients with 
first venous thrombosis, hyperthyroidism was discovered in the workup for venous 
thrombosis. If the FT4 levels  were normalized at the time of blood sampling, no 
effect on the risk for recurrence is expected. However, if the FT4 levels normalized 
after blood sampling and before recurrence, the risk estimate would be an 
underestimation of the true risk because high FT4 levels were used in the 
calculations while the actual FT4 levels were low most of the observation time. If FT4 
levels  would remain high over time, the point estimate would not be different since 
the levels of FT4 at blood sampling would reflect the level of FT4 at the recurrent 
event. If hyperthyroidism had developed after the first venous thrombosis  and no 
treatment was given, there is no error in the risk estimate. If there was treatment 
after blood sampling, misclassification of the exposure (high FT4 levels instead of 
normal levels) would have occurred which would have led to an underestimation of 
the risk for recurrence for high FT4 levels. For completeness, if FT4 levels  would be 
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normal over time, there would be no misclassification of the risk estimate for 
recurrence. To minimize the effect of such misclassifications, we performed the 
matched case-control analysis and, additionally, calculated ORs for different time 
windows between blood sampling and recurrent event. Shorter time between the two 
did not influence the relation that was found. However, despite all these measures to 
reduce misclassification, some residual misclassification cannot be excluded. 
Apart from these misclassification issues, there are several limitations that need to 
be addressed. Although the group of recurrent venous thrombosis was large 
compared with other studies, sub-analysis within the FT4 strata was difficult due to 
small numbers. We noted a high incidence of recurrent venous thrombosis in 
participants with a combination of FT4>23 and an unprovoked first thrombosis, which 
could be of interest and should be further examined in cohorts of patients in whom 
thyroid function is measured in more detail. 
Despite these limitations, we conclude that hyperthyroidism present at a first venous 
thrombotic event is  not a risk factor for recurrence. In line with other transient risk 
factors for a first event, it was even associated with a reduced risk of recurrence. 
This  emphasizes the need for awareness of possible hyperthyroidism in patients  who 
present with an unprovoked thrombotic event as well as in patients with such a 
history, so that the patient will not only benefit from recovery of thyroid disease but 
also from a reduced risk of recurrent venous thrombosis.
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Table 1. General characteristics
Recurrence (n=381) No recurrence (n=761)
Age (median years; p2.5 to p97.5) 50.5 (21.7 to 69.2) 48.1 (22.9 to 68.6)
Male (%) 236 (61.9) 332 (43.6)
Follow up (median days; p2.5 to 97.5) 1128 (147 to 3064) 2976 (642 to 3358)
Time from first VT to blood sampling 
(median days; p2.5 to 97.5)
310 (169 to 641) 310 (169 to 641)
TBSI (median days; p2.5 to p97.5) 757 (-265 to 2771) 1725 (68 to 2868)
FT4 (median; p2.5 to 97.5) pmol/l 16.7 (12.2 to 21.1) 16.7 (12.2 to 22.1)
TSH (median; p2.5 to 97.5) mU/l 1.31 (0.38 to 4.65) 1.36 (0.35 to 4.77)
n indicates number; p, percentile; VT, venous       
Time from blood sampling to recurrence or e         
stimulating hormone.
thrombosis; DVT, deep v
nd of follow-up; FT4, free
enous thrombosis; TBSI,
thyroxine; TSH, thyroid
Table 2. The r             
thyroid stimula  
isk for recurrent
ting hormone.
venous thrombosis for different strata of free thyroxine and
CFT4 FT4 (pmol/l) Controls Cases OR1 (CI95) OR2 (CI95)
<14 <15.5 210 86 0.8 (0.6 to 1.1) 0.8 (0.6 to 1.1)
14 to 17 15.5 to 18.9 407 220 Ref Ref
18 20.0 41 20 0.9 (0.5 to 1.5) 0.6 (0.4 to 1.2)
19 21.1 11 9 1.8 (0.7 to 4.9) 1.8 (0.7 to 4.8)
20 22.2 9 4 0.7 (0.2 to 2.3) 0.6 (0.2 to 2.0)
21 23.3 5 2 0.7 (0.1 to 3.5) 0.5 (0.1 to 2.5)
22 >24.4 3 2 0.7 (0.1 to 4.6) 0.6 (0.1 to 3.8)
Percentile TSH (mU/l) Controls Cases OR1 (CI95) OR2 (CI95)
>80 >2.03 143 66 0.9 (0.6 to 1.2) 0.9 (0.7 to 1.3)
20 to 80 0.84 to 2.03 395 203 Ref Ref
10 to 20 0.63 to 0.84 61 33 1.0 (0.6 to 1.6) 0.9 (0.5 to 1.5)
5 to 10 0.49 to 0.63 32 19 1.1 (0.6 to 2.0) 0.9 (0.5 to 1.6)
2.5 to 5 0.36 to 0.49 16 8 0.9 (0.4 to 2.1) 0.8 (0.3 to 1.9)
1 to 2.5 0.22 to 0.36 11 4 0.8 (0.2 to 2.5) 0.6 (0.2 to 2.0)
<1 <0.22 9 2 0.4 (0.1 to 2.0) 0.4 (0.1 to 1.8)
CFT4 indicates              







, free thyroxine; OR
: odds ratio adjusted
, odds ratio and TSH,
for age and sex.
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Table 3.              











strata of FT4 with varying time
CFT4 FT4 (pmol/l) Controls Cases OR1 (CI95) Controls Cases OR2 (CI95)
<14 <15.5 136 54 0.8 (0.6 to 1.2) 193 80 0.8 (0.6 to 1.1)
14 to 17 15.5 to 18.9 291 149 Ref 386 209 Ref
18 20.0 22 12 0.7 (0.3 to 1.5) 38 19 0.6 (0.3 to 1.2)
19 21.1 8 4 1.1 (0.3 to 4.0) 10 7 1.4 (0.5 to 3.9)
20 22.2 5 2 0.5 (0.1 to 2.9) 9 4 0.6 (0.2 to 2.0)
21 23.3 3 2 0.8 (0.1 to 5.3) 5 2 0.4 (0.1 to 2.4)
22 >24.4 0 1 na 3 2 0.5 (0.1 to 3.8)
Percent TSH (mU/l) Controls Cases OR1 (CI95) TSH (mU/l) Controls Cases OR2 (CI95)
>80 >2.10 91 42 1.0 (0.6 to 1.5) >2.03 129 63 1.0 (0.7 to 1.4)
20 to 80 0.86 to 2.10 276 131 Ref 0.83 to 2.03 370 191 Ref
10 to 20 0.64 to 0.86 40 22 1.0 (0.5 to 1.8) 0.62 to 0.83 69 32 0.7 (0.4 to 1.2)
5 to 10 0.50 to 0.64 20 10 0.8 (0.4 to 1.9) 0.48 to 0.62 24 18 0.9 (0.5 to 1.8)
2.5 to 5 0.35 to 0.50 13 8 0.9 (0.3 to 2.2) 0.36 to 0.48 18 6 0.5 (0.2 to 1.4)
1 to 2.5 0.24 to 0.35 6 3 1.0 (0.2 to 4.5) 0.22 to 0.36 8 4 1.0 (0.3 to 3.4)
<1 <0.24 6 1 0.3 (0.0 to 2.9) <0.22 9 1 0.2 (0.0 to 1.5)
CFT4 ind              
percentile               
sample w                  
1.5 year   
icates free t
and TSH, t
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Summary: Thyroid hormone, haemorrhage and venous 





At the end of this thesis  we present an overview incorporating the literature and the 
papers presented in this  thesis. This chapter focuses on the associations between 
hyperthyroidism and venous thrombosis, hypothyroidism and bleeding, 
hypothyroidism and venous thrombosis, the pathophysiology and clinical 
implications. In this overview we distinguish between case reports  and controlled 
studies, and between studies of clinically diagnosed thyroid disease and those of 
levels of thyroid hormones.  
On PubMed the following search terms were used to identify  studies on the relation 
between thyroid hormones and haemorrhage or venous thrombosis: venous 
thrombosis, thrombosis, embolism, pulmonary embolism, thyroid, thyroxine, 
haemorrhage and hemorrhage. Studies were included up to December 2013 and 
cross referenced. All controlled  studies on both FT4 levels or clinical thyroid disease 
and symptomatic venous thrombosis  were included leading to seven studies(table 1) 
[20,42,48,49,67,71,93]. No studies on thyroid disease and asymptomatic venous 
thrombosis  were found. Three of the studies considered clinically diagnosed thyroid 
disease: the study by Lin et al. [49] and Kootte et al. [93] looked at patients with 
hyperthyroidism, while the study by Danescu et al [71] included both hypo- and 
hyperthyroidism. Four studies  concerned the full spectrum of FT4 levels, rather than 
diagnoses of thyroid disease [20,42,48,67]. There was only one study on the risk of 
bleeding with low levels of free thyroxine (this thesis).
Hyperthyroidism
The relation between high levels of thyroid hormone or thyrotoxicosis and venous 
thrombosis  was first described in case reports in 1913 by Kaliebe et al. [13] and in 
1928 by Doyle et al. [94]. Other case reports appeared 
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Summary
Thyroid disease Author Year Exposure Outcome Study result
Hyperthyroidism Squizzato et al. 2007 FT4 levels Venous thrombosis no effect 
Debeij et al. 2012 FT4 levels Venous thrombosis elevated risk
van Zaane et al. 2010 FT4 levels Venous thrombosis elevated risk
Debeij et al. submitted FT4 levels Venous thrombosis elevated risk
Lin et al. 2010 Hyperthyroidism Venous thrombosis elevated risk
Kootte et al. 2012 Hyperthyroidism Venous thrombosis elevated risk
Danescu et al. 2009 Hyperthyroidism Venous thrombosis no effect 
Hypothyroidism Debeij et al. 2014 FT4 levels Haemorrhage elevated risk
Michiels et al. 2001 Hypothyroidism Haemorrhage elevated risk
Danescu et al. 2009 Hypothyroidism Venous thrombosis elevated risk
Squizzato et al. 2007 FT4 levels Venous thrombosis elevated risk
Debeij et al. 2012 FT4 levels Venous thrombosis elevated risk
van Zaane et al. 2010 FT4 levels Venous thrombosis reduced risk
Debeij et al. submitted FT4 levels Venous thrombosis elevated
Table 1: summary of identified studies and their exposures and outcomes. 
from time to time, mainly focusing on the relation between thyroid dysfunction and 
cerebral venous thrombosis  [14-18]. In a review of case reports published between 
1990 and 2009, Franchini et al. identified 34 case reports on hyperthyroidism and 
venous thrombosis [21]. Twenty-five of these reported on a case of cerebral vein 
thrombosis  (CVT). It is likely that this  rare form of thrombosis (1 per 100 000 person 
years [95]), rather than the occurrence of deep venous thrombosis or pulmonary 
embolism, raised questions on the aetiology and was subsequently deemed 
interesting to report on.
High FT4 levels and venous thrombosis risk
A first controlled study was performed in 2007 on the risk of deep venous thrombosis 
in 50 patients with provoked, 50 patients with unprovoked and 50 controls  with no 
venous thrombosis  [20]. No effect of hyperthyroidism on the risk for venous 
thrombosis was found in this small study.
Subsequently, three larger studies on the relation between thyroid hormone and risk 
of venous thrombosis have been performed: the ACT-study [42], the MEGA-study 
[67] and the TROL study [48], all using different study designs. All three studies 
collected blood samples and data on venous thrombosis. The most obvious 
difference in the design of the studies  was  the timing of the blood draw: In the TROL 
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study blood was  sampled before the thrombosis, in the ACT-study blood was drawn 
at the time of thrombosis and in the MEGA study blood was drawn with a minimum of 
3 months  after the thrombosis. In addition, the MEGA study has substantially more 
power than the other two studies due to a large number of patients with thrombosis.
The TROL study [48] is a nested case control study within the HUNT-2 cohort 
(n=66140). This is  a Norwegian cohort study where participants were included 
between 1995 and 1997. With follow-up untill 2002, cases of venous  thrombosis 
(DVT and PE) in this cohort were retrieved and matched with controls  in a 1:3 ratio. 
This  nested case control study included 515 cases with venous thrombosis and 1476 
controls. In these subjects  FT4 and TSH were measured. In the overall analysis an 
association between levels of FT4 and the risk of venous thrombosis was found with 
a relative risk of 1.3 (CI95 0.6 to 3.0) at the 90th percentile (FT4>15.5 pmol/l) rising to 
a relative risk of 2.5 (CI95 1.3 to 5.0) at the 98th percentile (FT4>17.3 pmol/l) 
comparing subjects with FT4 levels above the cut-off with subjects  with FT4 levels 
below this cut-off. Because the blood could have been sampled between 1 day to 
several months or years before the thrombosis, there could be misclassification of 
the FT4 level when this time period was very long because of variations in FT4 levels 
(regression dilution bias), masking a true effect. Indeed, at the higher percentiles of 
FT4, such an effect of time between blood sampling and the event was found. When 
only including cases in whom blood was drawn within 1 year before thrombosis, the 
OR at the 98th percentile rose from 2.5 to 4.8 (CI95 1.7 to 14.0). Restricting this time 
to half a year, this OR was 9.9 (CI95 2.9 to 34.0), indicating that the closer the blood 
sampling to the event, the lesser the misclassification and the stronger the effect. 
In the ACT study [42] FT4 levels  and triiodothyronine (T3) levels  were measured at 
the time of thrombosis  in 190 cases and 379 controls. The authors reported that 
higher levels  of FT4 gave rise to an increased risk of venous thrombosis, also in a 
dose response relation. A 1.7 fold increased risk (CI95 1.0 to 2.9) of venous 
thrombosis  was observed in patients with FT4 above the 90th percentile (>18 pmol/L) 
compared with patients with a FT4 level beneath the 90th percentile. At the 99th 
percentile (>22 pmol/L) this  risk increased to 4.7 (CI95 1.2 to 18.6). This effect was 
also seen for levels of T3, although less pronounced.
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In the MEGA study [67], 2177 cases with venous thrombosis and 2826 controls were 
included in the analysis. Blood was drawn several months after the venous 
thrombosis. Here also a dose response relation was  found with an OR of 1.2 (CI95 
0.9 to 1.6) at the 90th percentile, gradually rising to an OR of 2.2 (CI95 1.0 to 4.6) at 
FT4 levels >24.4 pmol/L compared with FT4 levels between 15.5 pmol/L and 18.9 
pmol/L (reference category). In the MEGA study, blood could have been drawn at 
various time points from the thrombotic events  (3 months  to 36 months). When only 
participants with blood drawn within 6 months after the event were included, the OR 
was 2.6 (CI95 0.7 to 9.6) at FT4 levels  >24.4 pmol/L compared with the reference 
category. When only subjects were included in whom hyperthyroidism was 
established, by clinical diagnosis or blood draw, less than one year before or shortly 
after the index date, an odds ratio of 17.0 (CI95 2.2 to 133.0) was found. 
Importantly, in all three studies, the increased risks for thrombosis were found for 
FT4 levels within the reference range.
Clinical  hyperthyroidism and venous thrombosis risk
According to our search, only three studies reported on the relationship between 
clinically diagnosed hyperthyroidism and venous thrombosis. In a population based 
cohort from Taiwan, only focusing on pulmonary embolism, Lin et al. [49] included 
participants with hyperthyroidism over a 5 year period. A total of 8903 patients were 
found. They were compared to 44515 participants without hyperthyroidism. Fourteen 
patients  with hyperthyroidism developed a pulmonary embolism (0.16%) as 
compared with 27 euthyroid participants  (0.06%). They found that patients with 
hyperthyroidism had a 2.3-fold increased risk for pulmonary embolism compared 
with euthyroid subjects (CI95 1.2 to 4.5). The study by Kootte et al. [93] estimated 
the incidence of venous thrombosis in hyperthyroid patients  in three hospitals in the 
Netherlands and found an incidence rate for first venous thrombosis of 5.3  per 1,000 
person-years (CI95 1.1 to 15.6), which was considered to be higher than the 
population incidence of 1 per 1000 person-years [93]. A study by Danescu [71] et al 
was performed in the National Hospital Discharge Survey USA from 1979 to 2005. 
They looked at the discharge codes for hypothyroidism, hyperthyroidism, pulmonary 
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embolism and deep venous thrombosis.  No increased risk for venous thrombosis 
with a relative risk of 0.98 (CI95 0.96 to 1.01) was found in patients with a diagnosis 
of hyperthyroidism compared to patients without a diagnosis  of thyroid dysfunction in 
the database. 
Hypothyroidism
In 25 case reports, as summarized by Galli-Tsinopoulou et al. [86] from 1987 to 
2006, an association was reported between acquired von Willebrand disease, i.e., 
low levels of von Willebrand factor, and hypothyroidism. Of these case reports  10 
patients showed only laboratory abnormalities, and 15 patients presented with 
clinical symptoms as menorrhagia, epistaxis, bruising and excessive bleeding after 
dental extraction. A  similar evaluation was made by Manfredi et al. further 
investigating the  association between bleeding, acquired von Willebrand disease 
and hypothyroidism [45]. 
Low FT4 levels and haemorrhage
Apart from these case-reports, only two controlled studies addressed the question on 
the risk of bleeding with low levels of free thyroxine. In the Factors study (this thesis), 
a 1:2 matched case-control study with 330 participants using vitamin K antagonists, 
a 5-fold increased risk for major bleeding was found for patients  with FT4 levels 
<13.3 pmol/l and a 3-fold increased risk for FT4 levels  <14.4 pmol/l. The other paper 
reports on patients with a combination of acquired von Willebrand disease and 
hypothyroidism. By normalizing levels of FT4 using levothyroxine, the low levels of 
VWF and FVIII also returned to normal [34].
Clinical hypothyroidism and venous thrombosis
If the effect on bleeding of low FT4 levels is  causal, low levels of FT4 could translate 
in a protective effect against venous thrombosis. However, both a pro- and an anti-
thrombotic effect of low levels  of FT4 have been described. Peralta et al. claimed a 
role for hypothyroidism in the aetiology of cerebral vein thrombosis, by describing 
two cases with hypothyroidism concomitantly diagnosed with cerebral venous 
thrombosis  [96]. The study by Danescu et al. reported no risk for venous  thrombosis 
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with the diagnosis  of hyperthyroidism as  mentioned before, but did report on an 
increased risk for venous thrombosis with the diagnosis of hypothyroidism. An 
increased risk of 1.60 (CI95 1.59 to 1.60) was reported for patients diagnosed with 
hypothyroidism compared with participants without thyroid dysfunction. 
Low FT4 levels and venous thrombosis
The first controlled study on risk of venous thrombosis  was done by Squizzato et 
al[20]. In patients  with unprovoked deep venous thrombosis, a 5.5-fold increased risk 
(CI95 0.6 to 52.6) for subclinical hypothyroidism was found. In provoked DVT 
patients a 6.8-fold higher chance to find subclinical hypothyroidism was found 
compared with controls. However, this study was small, so that chance findings were 
plausible.
In contrast, in the ACT study, where blood was sampled at the time of the event [42], 
a linear relationship between the risk of venous thrombosis  and FT4 levels  was 
found with a protective effect of low levels of thyroid hormone (FT4 < 15 pmol/l) . At 
the 10th percentile (FT4<13 pmol/l), there was a 2-fold decreased risk (OR 0.5 CI95 
0.2 to 1.0) for venous thrombosis, while at the 5th percentile (FT4<12 pmol/l) a 10-
fold decreased risk was found (OR 0.1 CI95 0.0 to 0.9).
In the MEGA [67] and the TROL study [48], the results were more difficult to 
interpret. In the MEGA study we studied the effect of low levels of FT4 on the risk of 
venous thrombosis (this  thesis). In the overall analyses, we found an OR of 1.8 (CI95 
1.0 to 3.1) comparing FT4 levels  of 11 pmol/L to the reference category of levels 
between 15 and 19 pmol/L. At FT4 levels <10 pmol/L an OR of 2.5 (CI95 0.9 to 6.7) 
was seen. Similar observations were made in the TROL study[48]. In the overall 
analysis, a mildly increased thrombosis risk of 1.4 (CI95 1.0 to 1.9) was found at the 
10th percentile cut-off of FT4 (<11.7 pmol/l) comparing subjects below with subjects 
above this  cut-off. At the 1st percentile, using the same comparison with a cut-off of 
10.7 pmol/l an OR of 1.3 (CI95 0.7 to 2.8) was found. Summarizing, the slightly 
increased risk that was found in the TROL and the MEGA study for low levels  of FT4, 
reversed or attenuated to unity in the TROL study when only a short period between 
thrombosis and blood sampling was taken. 
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Pathological considerations
There is not much known on the pathophysiological mechanisms underlying the 
effect of thyroid hormones on the coagulation system. Thyroid hormone affects  gene 
transcription, which may form the basis of changes in pro- and anticoagulant 
proteins. Since thyroid hormone influences the basal rate of the carbohydrate, lipid 
but also the protein metabolism, it is likely that thyroid hormone also affects the 
production and clearance of coagulations proteins. In vitro studies have shown a 
direct effect of tri-iodothyronine (T3) on hepatocytes and endothelial cells. T3 causes 
an up-regulation of fibrinogen, factor II (prothrombin), factor X, von Willebrand factor 
and plasminogen [36,66,69]. Also in vivo, a quick response of the coagulation 
system was seen with increased production of nearly all coagulation factors, but 
most notably VWF and FVIII, on increasing levels of FT4 caused by restarting 
levothyroxine substitution after withdrawal [46,47]. Additional proof comes from a 
clinical study [67], where we found a positive association between FVIII and VWF 
with levels of FT4. Also the risk for venous thrombosis  attenuated upon adjustment 
for FVIII and VWF, which suggests  that VWF and FVIII are in the causal pathway 
between thyroid hormone and venous thrombosis. Although not much is known 
about the relation between thyroid specific auto-immune antibodies and the effect on 
the coagulation system, some claims of an effect via this  pathway have been made. 
In this thesis, we have looked in 3 different studies whether there was  an effect of 
anti-thyroid peroxidase antibodies on the risk of thrombosis. None of the studies 
were able to find a relation between these antibodies and venous thrombosis. A third 
mechanism was recently proposed by Hooper et al. [81] who studied the influence of 
thyroxine on fibrin formation. A cross-over design was applied with two arms: Blood 
was sampled from 19 patients with hyperthyroidism en from 19 euthyroid matched 
controls. Another blood sample was gathered after treatment of the hyperthyroid 
patients, i.e., when they returned to a euthyroid state. Levothyroxine was added to 
the blood samples of the euthyroid participants. In hyperthyroidism, a dense clot 
structure with impaired fibrinolysis was found. The clot structure partly returned to 
normal when a euthyroid state was restored. Short term exogenous hyperthyroidism 
was not associated with alterations in clot structure. Inflammation may also play a 
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role because complement C3 levels were also associated with clot formation in 
hyperthyroid patients.  The denser clot structure and higher resistance to fibrinolysis 
might, in itself or in combination with faster clot formation as hypothesized earlier, 
also be a plausible explanation for the clinical effects found.
The last pathophysiological explanation is the association between hypothyroidism 
and cardiovascular risk factors. These cardiovascular risk factors include obesity, 
LDL cholesterol, mild increases of homocysteinemia and endothelial dysfunction; 
hypothyroidism also increases diastolic blood pressure and induces a mild increase 
in C-reactive protein [59,60,62,63]. Since recent reports state that arterial 
cardiovascular risk factors also tend to increase the risk for venous thrombosis to 
some extent [87-89], it might be possible that these cardiovascular parameters are 
somewhere in the pathway between hypothyroidism and venous thrombosis. 
The effect of low levels of free thyroxine via cardiovascular risk factor would result in 
a pro-thrombotic effect, while the direct effect of hypothyroidism on the coagulation 
system is anti-coagulant.
There are several directions  for further research. First, the finding of an increased 
risk of bleeding in patients with low levels of FT4 using VKA needs to be confirmed in 
larger cohorts, including patients treated with other anticoagulants. Second, since 
the relation between high levels  of FT4 and venous  thrombosis risk is now well 
established, research needs  to be aimed at the clinical implications of this  relation. 
Does FT4 need to be included in the standard workup protocol for unprovoked 
venous thrombosis? Would treatment of hyperthyroidism levels lead to modification 
of the risk of venous thrombosis? Is anti-coagulation needed in patients  with high 
FT4? Or is  anti-coagulation therapy needed in hyperthyroid patients  before surgery? 
It is also interesting to see what the risk of venous thrombosis is in clinical 
hyperthyroid patients compared to euthyroid persons in a larger patient sample. 
Furthermore, more work needs to be done to uncover the specific pathways in which 
FT4 influences the coagulation system.
In conclusion, in the studies  in this thesis we found strong evidence that higher than 
average levels  of FT4 increase the risk of venous thrombosis. Weak evidence is 
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provided that lower than average levels of FT4 give an increased risk of bleeding in 
patients using vitamin K antagonists. A hypothyroid state possesses probably both 
pro- and anti-coagulant properties. The effect of FT4 on venous thrombosis is 
mediated at least by coagulation factors factor VIII and von Willebrand factor.
Clinical implications
Most of the FT4 levels where an increased risk for venous  thrombosis  is  found are 
within the FT4 range that will be left untreated in clinical practice. Thus, findings of 
these FT4 levels would in itself have no clinical consequences, but could be used in 
constructing an overall risk profile.
The relation between free FT4 and the risk of venous thrombosis  has implications  for 
both physicians  treating venous thrombosis  and physicians treating endocrine 
disorders. The most important clinical implication is that physicians should be aware 
of the relation. When treating patients  with hypothyroidism, physicians must be 
aware of symptoms such as easy bruising, gum bleeding etcetera, suggesting 
aqcuired von Willebrand disease. Although the evidence is not very strong, it 
suggests that with levothyroxine substitution therapy, coagulation factors return to 
normal [34,46,47]. At the other end of the spectrum, when treating patients with 
hyperthyroidism, physicians need to be aware of symptoms of deep venous 
thrombosis  and pulmonary embolism. Especially in situations with an elevated risk 
for venous thrombosis such as surgery or pregnancy, patients with hyperthyroidism 
should be monitored closely. Early referral for treatment will be beneficial for the 
patient. 
For physicians treating patients  with thrombosis, there are several clinical 
implications. In patients  with venous thrombosis, it is advisable to look for signs of 
thyroid disease, such as goiter, sweating, heat or cold intolerance etc. Based on our 
and the above mentioned previous  findings in three other studies [42,48,49], routine 
testing for hyperthyroidism of patients with an unprovoked thrombosis may be 
considered, as the diagnosis  is not always obvious clinically and testing is easily 
done and relatively cheap. A positive result will have a strong impact for the patient: 
113
Summary
not only will an undetected condition be treated, but also can the patient receive 
anticoagulant treatment for a shorter period (3 instead of 6 months (ACCP guidelines 











Veneuze trombose is een ziekte die veel voorkomt. Met een incidentie van ongeveer 
1 per 1000 persoonsjaren, is het een ziekte met een hoge morbiditeit en mortaliteit. 
Een trombose vormt zich vaak in het diepe veneuze systeem van het been, het 
wordt dan een diepe veneuze trombose genoemd. Een trombose kan zich echter 
ook in de meer centrale vaten vormen of in de arm. Als een veneus gevormd stolsel 
losschiet, loopt het vast in het eerste vernauwde vaatsysteem op zijn route: het 
longbed. Een stolsel in het longbed wordt een longembolie genoemd. Aangezien een 
longembolie een obstructie geeft van de bloedstroom door de longen, is het een 
belemmering voor de zuurstofuitwisseling tussen bloed en buitenlucht. Hierdoor 
ontstaat er een disbalans tussen ventilatie en perfusie en kan een patiënt te weinig 
zuurstof opnemen. Veel risicofactoren voor het krijgen van veneuze trombose zijn 
bekend. Deze zijn gemakshalve onder te verdelen in genetische risicofactoren en 
verworven risicofactoren. Bij genetische risicofactoren moet bijvoorbeeld gedacht 
worden aan een protrombine-mutatie of de factor V Leiden-mutatie. Mensen met 
deze mutaties hebben een verhoogd risico op het krijgen van een veneuze 
trombose. Verworven risicofactoren zijn onder anderen onderbeensgips, kanker, 
immobilisatie, een recente operatie en zwangerschap. Als therapie ter voorkoming 
van een recidief veneuze trombose, danwel vanwege een andere indicatie zoals 
atriumfibrillatie, een pacemaker of bypass chirurgie, kan antistollingsmedicatie 
gegeven worden. Deze medicatie remt het stollingssysteem op bepaalde punten 
teneinde de vorming van stolsels te voorkomen. Een voor de hand liggende 
bijwerking is een verhoogd risico op bloeding. Dit kunnen kleine bloeduitstortingen 
zijn, maar dit kan zich ook manifesteren als bloedingen in gewrichten of in het brein. 
Dit kan resulteren in onomkeerbare schade en zelfs overlijden.!
!
De laatste jaren is er meer aandacht gekomen voor de invloed van endocriene 
hormonen op het krijgen van een veneuze trombose. Daarbij moet gedacht worden 
aan cortisol, groeihormoon, prolactine en schildklierhormoon. In dit proefschrift wordt 
gekeken naar de invloed van schildklierhormoon op de individuele stollingsfactoren 




De eerste beschrijving van een relatie tussen schildklierhormoon en veneuze 
trombose stamt uit 1913. In dit artikel wordt een patiënt beschreven die een 
cerebrale veneuze trombose heeft tezamen met een ernstige hyperthyreoïdie. In de 
loop der tijden zijn er meerdere van deze studies beschreven. Opmerkelijk genoeg 
worden vaak cerebrale veneuze tromboses beschreven. Waarschijnlijk vanwege het 
zeldzame karakter van deze aandoening, in combinatie met de desastreuze 
gevolgen die dit ziektebeeld met zich mee brengt. Naast deze patiëntrapportages is 
er ook nog gekeken naar het effect van schildklierhormoon op de verschillende 
stollingsfactoren van het stollingssysteem. Hierbij wordt gezien dat een verhoging 
van het schildklierhormoon gepaard gaat met een verhoging van in ieder geval 
stollingsfactoren factor VIII, von Willebrand factor en fibrinogeen. Een individuele 
verhoging van deze factoren leidt tot een hogere activiteit van het stollingssysteem, 
hetgeen kan leiden tot een verhoogd risico op vorming van een veneuze trombose. 
Pas in 2007 werd het eerste klinisch onderzoek verricht naar de relatie tussen 
schildklierhormoon en veneuze trombose. In deze studie werd geen associatie 
gevonden tussen beiden. Opgemerkt dient te worden dat er zo weinig patiënten in 
het onderzoek zaten dat er alleen een effect gevonden kon worden als dit heel groot 
bleek te zijn. Kort daarop zijn drie verschillende grotere studies gepubliceerd om 
meer te weten te komen over de relatie tussen schildklierhormoon en veneuze 
trombose. Het grote verschil tussen deze drie studies is het moment waarop bloed 
bij de patiënt werd afgenomen in verhouding tot het ontstaan van de trombose. In 
het grote Noorse HUNT cohort werd bloed afgenomen bij ongeveer 66.000 mensen. 
Gekeken werd welke mensen later een trombose kregen. Daarbij werden controles 
gezocht. Er werd gevonden dat personen met de hoogste schildklierhormoon-
waarden een ongeveer 2,5 keer zo hoog risico hadden op het krijgen van veneuze 
trombose. Bij een korte tijd tussen het afnemen van bloed en het optreden van een 
trombose (waarbij de gemeten waarde van het schildklierhormoon meer 
waarschijnlijk de waarde ten tijde van trombose is), nam dit toe tot een ongeveer 10 
keer verhoogd risico. In de ACT studie werd bloed afgenomen op het moment dat 
patiënten een trombose hadden. Hier werd een 5 keer verhoogd risico gevonden op 
het optreden van een veneuze trombose bij hoge schildklierhormoonwaarden. In de 
MEGA studie werd het bloed ter bepaling van schildklierhormoonwaarde enkele 
maanden na de trombose afgenomen. Hier werd een 2 keer verhoogd risico 
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gevonden. Als ook hier alleen patiënten meegenomen werden met weinig tijd tussen 
de trombose en de bloedafname, nam het risico toe tot ongeveer 2,5. Als enkel de 
groep werd bekeken met hoge schildklierhormoonwaarden ten tijde van de trombose 
werd zelfs een 17-voudig verhoogd risico gevonden. Al deze 3 studies vinden dus 
een verhoogd risico op het krijgen van een veneuze trombose bij verhoogde 
waarden van schildklierhormoon. Hoog schildklierhormoon, of hyperthyreoïdie, kan 
dus beschouwd worden als een risicofactor voor veneuze trombose. !
!
Ook is er gekeken naar het effect van laag schildklierhormoon, hypothyreoïdie, op 
het stollingssysteem. In een review van de beschikbare literatuur werd gezien dat 
globale stollingstesten zoals de aPTT en de PT(INR) verhoogd zijn bij lagere 
waarden van schildklierhormoon. Hogere waarden van deze stollingstesten houden 
in dat bloed moeilijker stolt. Daarnaast werd ook gezien dat er, in tegenstelling tot de 
stijging bij hyperthyreoïdie, een daling optreedt van stollingsfactoren factor VIII, von 
Willebrand factor, fibrinogeen en factor IX. Een daling van deze waarden zou kunnen 
leiden tot een verhoogde bloedingsneiging. Deze verhoogde bloedingsneiging kon 
teniet gedaan worden door het normaliseren van de schildklierhormoonwaarden met 
medicatie. Er is maar één klinische studie verschenen over de relatie tussen lage 
schildklierhormoonwaarden en een verhoogde bloedingsneiging. Bij lage 
schildklierhormoon waarden werd een 5 keer verhoogd risico gevonden op het 
ontwikkelen van een ernstige bloeding (bijvoorbeeld een gewrichtsbloeding of een 
hersenbloeding) in patiënten die al anti-stollingsmedicatie gebruikten. Met een 
verhoogde bloedingsneiging gaat een verminderde stollingsneiging gepaard, 
hetgeen een beschermend effect kan hebben op het ontwikkelen van een veneuze 
trombose. Ook hiernaar is gekeken. Uit patiëntrapportages blijkt dat hypothyreoïdie 
geduid wordt als zowel een risicofactor alsook een beschermende factor voor een 
veneuze trombose. Ook uit de recente klinische studies waar gekeken is of laag 
schildklierhormoon een beschermende factor danwel een risico factor is, volgt geen 
eenduidig antwoord. In het geval dat laag schildklierhormoon een risicofactor is voor 
het optreden van een bloeding en een beschermende factor voor een veneuze 
trombose, zou dit in lijn zijn met lage stollingsfactoren die worden gevonden bij lage 
schildklierhormoonwaarden. Als laag schildklierhormoon een risicofactor blijkt te zijn 
voor het optreden van een trombose, zou het beschermende effect van de lage 
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stollingsfactoren tegengewerkt moeten worden. Hypothyreoïdie is, behalve met lage 
stollingsfactoren, ook geassocieerd met cardiovasculaire risicofactoren zoals 
obesitas, hoog LDL cholesterol, diastolische hypertensie, verminderde 
endotheelfunctie en inflammatie. Via deze factoren zou het beschermende effect van 
lage stollingsfactoren teniet kunnen worden gedaan en zelfs een trombose neiging 
kunnen ontstaan. !
!
Hoewel is aangetoond dat er een relatie bestaat tussen schildklierhormoon en 
veneuze trombose is het nog te vroeg om er strikte klinische consequenties aan te 
verbinden. Wel is van belang dat zowel haematologen als endocrinologen op de 
hoogte zijn van de relatie. Haematologen zouden een aan schildklierhormoon 
toegeschreven trombose na behandeling van de schildklierziekte kunnen 
beschouwen als een passagère risicofactor. Hierdoor zou de preventieve 
antistollingsbehandeling kunnen worden ingekort, waardoor het risico op 
bijwerkingen, met als belangrijkste bloeding, afneemt. Endocrinologen zouden door 
kennis van de associatie bij een patiënt met hyperthyreoïdie sneller een veneuze 
trombose kunnen diagnostiseren.! !
!
Concluderend is er een effect van hoge schildklierhormoonwaarden op het risico van 
een veneuze trombose. Op basis van de huidige literatuur en (basale) onderzoeken 
lijkt het er op dat lage schildklierhormoonwaarden een beschermend effect hebben 
op het ontstaan van trombose en een hoger risico op bloeding geven in patiënten die 
anti-stollingsmedicatie gebruiken. Welk mechanisme ten grondslag ligt aan het 
gevonden effect is nog niet duidelijk. Naar dit pathofysiologisch mechanisme moet 
dan ook nog meer onderzoek gedaan worden. Verdere richtingen voor verder 
onderzoek zijn: het repliceren van de verhoogde bloedingsneiging bij lage 
schildklierhormoonwaarden bij anti-stollingsmedicatie in een groter cohort, de 
klinische implicaties van de gevonden relatie en het onderzoeken van het risico op 
veneuze trombose in een groep patiënten met klinische hyperthyreoidie. !
!
Resumerend: !
1) Er is sterk bewijs dat hoge schildklierhormoonwaarden een verhoogd risico geven 
op veneuze trombose. !
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2) Er is zwak bewijs dat lage schildklierhormoonwaarden een verhoogd risico geven 
op bloeding in patiënten die anti-stolling gebruiken. 
3) Het effect van schildklierhormoon op het stollingssysteem loopt voornamelijk via 
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